Clinical Dental Practice — Learning Objectives

How to read this sheet

Each objective is a broad competency statement followed on the same line by an italicised split: High-yield = the specific facts, numbers, and named classifications most likely tested in exams or critical in clinic; Lower = background, niche, or contextual detail. Bold inside a High-yield list flags the single highest-yield point of that objective.

Exam context

The combined CDP + Perio exam is 2 hours: CDP = 8 scenario-based SAQs (medical-history interpretation, diagnosis, treatment options/planning, material selection, decision-making); Perio = 30 MCQs (covered separately). Yield here is weighted by GDP Exam Tips and by each topic’s emphasis. Course Lectures (L1–L4) cover the in-class material; the two Resources sections that follow expand the high-yield treatment-planning and pharmacology content the SAQs draw on, sourced from Resources for Treatment Planning and Resources for Pharmacology.

Course Lectures

L1: Articulators

Explain the function and indications of an articulator (mechanical instrument representing the TMJs/jaws to which casts are mounted to simulate mandibular movements). High-yield: mounting indicated for >2 single crowns/bridges, RPDs, complete & immediate dentures, and any case increasing VD (wax-up); functions = simulate movement, work without patient present, design occlusal harmony, reduce chairside adjustment time. Lower: single crowns may be optional if occlusion stable + confirmative approach; occlusal splints unless CAD-CAM; diagnostic articulation assesses occlusal plane/contacts/space.
State the limitations of articulators and why intraoral checks remain essential. High-yield: cannot replicate complex tissues, joints, and neuromuscular control; the masticatory system is the “ultimate articulator” so fine adjustments are finalised in the mouth. Lower: even advanced articulators only simulate, never fully replicate, all movement combinations.
Classify articulators by instrument function into Classes I–IV. High-yield: Class I = hinge (vertical only, no facebow); Class III = average (semi-adjustable, accepts facebow); Class IV = special (3-D dynamic/pantographic, fully adjustable). Lower: Class II = arbitrary (horizontal + vertical but no condylar guidance/Bennett adjustment); Class I = simplest, single static registration, simple restorations only.
Classify articulators by adjustability and link each to clinical use. High-yield: non-adjustable (Class I) → simple single crowns; semi-adjustable (Class III) → most fixed/removable prosthetics; fully adjustable (Class IV) → severe malocclusion/teaching, rarely used. Lower: semi-adjustable adjusts condylar guidance incline, Bennett angle, incisal guidance, intercondylar distance; non-adjustable risks “high” restorations/premature contacts due to short distance from hinge axis; semi-adjustable arc of closure better matches patient’s radius of movement.
Compare ARCON and NONARCON semi-adjustable articulators. High-yield: ARCON = condyle on lower member, fossa on upper → condylar inclination stays fixed to maxillary occlusal plane regardless of opening (resembles true TMJ; e.g. Kavo Protar, Whip Mix); NONARCON = condyle on upper, fossa on lower → condylar angle changes on opening, introducing errors in eccentric/protrusive checks (e.g. Hanau, Dentatus). Lower: NONARCON components rigidly attached so easier to handle; “Ar”-ticulator + “con”-dyle mnemonic.
Describe the facebow’s purpose and recording procedure. High-yield: records the anteroposterior + mediolateral position of the maxillary occlusal plane relative to the horizontal (hinge) axis of mandibular rotation and the cranial base; caliper-like instrument; bite-fork impression of maxillary cusp tips → position fork → adapt bow to face width → nasal support on nasion. Lower: edentulous cases need base + wax rim for posterior support; Kavo Protar uses nasal support averaging Frankfurt & Camper’s planes (Frankfurt = infra-orbital + porion, Camper’s = subnasal + tragus); Protar bite-fork post offset to the left, not midline; pointer above bow for Frankfurt, below for Camper’s.
Explain why facebow mounting matters for OVD changes. High-yield: with facebow the casts sit at correct distance from the hinge axis, so altering OVD on the articulator (e.g. 3 mm at the pin) accurately reflects anterior/posterior reduction in the mouth. Lower: without facebow, casts mounted too close/far from hinge axis cause incorrect tooth reduction (too much/too little) and restorations that don’t fit the bite; incorrect intercondylar settings (S/M/L) cause cusp interference in lateral movements.
Describe bite registration in CR vs MIP and when to mount in each. High-yield: confirmative approach (stable bite, no TMD) → mount/treat in MIP; reorganised approach (unstable bite, lost VD, TMD signs) → mount/treat in CR. Lower: CR = condyle most anterior-superior in fossa, a reproducible tooth-independent position; “freedom in centric” reorganises in CR but leaves restorative freedom between CR and habitual MIP; CR techniques include tongue-tip to soft palate, leaf gauge, Lucia jig, Kois deprogrammer, anterior jig; record materials need durability/rigidity/ease (wax, silicone, ZnO-eugenol, resin), V-notch wax rims to key material.
Explain the role of a Lucia jig / anterior deprogrammer in obtaining CR. High-yield: small anterior acrylic device that prevents posterior contacts and de-programs the masticatory muscles, breaking habitual “muscle memory” so the clinician can guide the jaw into CR. Lower: leaf gauge uses stacked strips between anterior teeth to disclude posteriors and seat condyles superior-anteriorly; alternatives = occlusal splint, Kois deprogrammer, anterior jig.
Describe programming of a semi-adjustable articulator and the consequences of errors. High-yield: program with eccentric records — protrusive sets condylar guidance (start 0°, advance fossa to just hold thin paper); Bennett angle set to ~30° on the non-working side (use LEFT lateral record to set RIGHT Bennett angle). Lower: sequence = 0° for cast mounting, pre-adjustment 30°, then final adjustment; improper use causes occlusal problems, incorrect articulations, treatment delays and extra appointments; if mounted models don’t match the patient’s mouth, do not send to lab — remount.

L2: Intraoral Scanning (Trios)

Describe the evolution of intraoral scanners (IOS) from early static-image systems to modern real-time handheld units, and explain why hardware has plateaued while software advances. High-yield: ~40-year history, first commercial system was the Cerec (1985), early scanners stitched individual static images into a 3D mesh (poor fit, heavy ~40 kg, lots of cement), modern units use gaming/crypto-derived GPUs for real-time rendering, Trios 5 is wireless/handheld/more accurate. Lower: 3M Lava COS (2008/2010), 3Shape Trios Wireless (2018), software focus now on AI and tissue differentiation.
Explain the core capture technologies and how raw optical data becomes a viewable 3D model. High-yield: triangulation (light beams projected, sensor measures reflection angle to fix points in 3D space) and confocal microscopy as the two main acquisition methods, thousands of captured points form a point cloud averaged into a polygon mesh rendered with artificial light/shadow. Lower: variants listed (triangulation LED, triangulation RGB, parallel confocal), meshes rendered for visual realism only.
Define resolution in IOS terms and relate it to finish-line detail. High-yield: resolution = density of the polygon mesh (number of triangles), higher resolution = better margin detail. Lower: hardware quality has plateaued like smartphone iterations, gains now come from software/AI rather than optics.
Explain the “what you see is what you get” principle and the monochrome-review recommendation for verifying margins. High-yield: if the operator cannot see the prep clearly with the naked eye (blood, saliva, tissue), the scanner cannot see it either, review preps in monochrome mode because colour “bleeding” obscures the true margin, magnify on-screen to detect stitching artifacts (“double layers”) before finishing. Lower: artifacts arise when the scanner loses its place during stitching, finish-line distinctness is the quality benchmark.
Explain the limitations of IOS at subgingival margins and when to revert to a conventional impression. High-yield: subgingival margins are the greatest challenge for IOS, if a margin is more than 0.5–1.0 mm subgingival a conventional impression may be more reliable, scanners cannot see through tissue or fluids. Lower: capture a small portion of root surface below the finish line for the emergence profile, scan quickly to reduce artifacts from unstable/moving tissues.
Interpret the accuracy/precision evidence comparing IOS to conventional impressions, distinguishing in vivo from in vitro performance. High-yield: IOS can replace conventional impressions when restoring up to ~10 units without extended edentulous spans (Nedelcu et al., in vivo), in vitro lab tests overestimate accuracy whereas in vivo factors (tongue, saliva, limited opening) reduce precision, full-arch reconstructions still favour conventional/specialised protocols due to cumulative stitching error. Lower: accompanying in vitro study compared 7 IOS vs conventional impression for finish-line distinctness, clinicians must critically evaluate the digital impression for technical limitations especially in challenging subgingival conditions.
List the clinical cases suitable for intraoral scanning. High-yield: diagnostics & treatment planning (virtual or 3D-printed models), single crowns, onlays, splints, short bridges, implants are ideal (no subgingival margins to retract). Lower: custom impression trays for difficult edentulous ridges (scan then 3D-print), special cases.
Apply the 3Shape scan strategy for the maxilla and mandible, including the swipe sequence and supporting techniques. High-yield: three swipes per arch — maxilla = occlusal, buccal, palatal; mandible = occlusal, lingual, buccal (scan lingual before buccal so it’s captured before saliva pools / tongue moves), start on the molar occlusal and wait 3–5 clicks, rotate 60–90° at the last molar to change surfaces, “wiggle” at the incisal edges to capture thin buccal+palatal/lingual aspects, use an OptraGate/retraction because the scanner can’t distinguish fixed from moving tissue. Lower: move smoothly without jumping, optional palate swipe side-to-side behind the incisors, use the tip to hold the tongue away.
Compare the main IOS output file formats and their uses. High-yield: STL (Standard Tessellation Language) = universal CAD/CAM format, monochromatic, used for milling/3D printing; PLY (Polygon File Format) = newer, includes colour-mapping data, more compact but less universal; DCM = proprietary 3Shape format for rotating/zooming/adjusting transparency in the 3Shape Viewer. Lower: students should review DCM scans with tutors on-screen rather than relying on physical models.
Describe the OCHWA/university lab workflow for submitting scans to production. High-yield: because the system uses a shared student account, you must enter your Name and Student ID in the scan “Notes” field, a physical paper slip is still required to trigger production/file export, files go to the lab for 3D printing (models) or milling (crowns/splints). Lower: milling/printing done on machines such as the Ivoclar PM7, scanning proficiency is “pilot-dependent” (~100 scans to become proficient, full arch in 15–20 seconds).

L3: Occlusal Splints

Define occlusal splints and explain their therapeutic indications across the masticatory system (removable appliances prescribed only after a definitive diagnosis — not every patient needs one). High-yield: bruxism/parafunction management, muscle relaxation by altering vertical dimension to deprogram muscles, protection of teeth and restorations (veneers/full-mouth rehab), TMJ stabilisation of clicking joints, fremitus management in periodontally compromised teeth. Lower: relief of fatigued muscles and headaches, malocclusion-related interference discomfort, prescription must follow diagnosis and consider long-term-use risks.
Describe the splint materials and their handling/clinical trade-offs. High-yield: hard acrylic (self-cured, heat-cured, or milled — milled is the current mainstay) is rigid and adjustable; soft/resilient is silicone-based and contraindicated long-term; dual-laminated (Talon) = hard occlusal surface + soft tissue-borne liner, not recommended in TMD. Lower: nylon as an alternative for methyl-methacrylate-allergic patients but difficult to adjust chairside, soft material likened to thickened whitening trays.
Classify occlusal appliances using both the Okeson and Dawson systems. High-yield: Okeson = (1) stabilisation/muscle-relaxation appliance, (2) anterior repositioning appliance, (3) other (anterior/posterior bite planes, pivoting, soft/resilient); Dawson = permissive (muscle deprogrammers), non-permissive (directive), pseudo-permissive (soft + hydrostatic). Lower: stabilisation = passive/permissive allowing free movement vs active repositioning devices, hydrostatic = water-filled and rarely used, pivoting appliances pivot the mandible in a set direction.
Explain the stabilisation (Michigan/Tanner) appliance design, function and arch selection — the most commonly used, “fall-proof” splint. High-yield: permissive splint giving uniform/even/simultaneous contacts (even posterior contacts in retruded position, lighter anterior), completely flat occlusal surface with no cusp indentations, canine/anterior ramps to disocclude posteriors in excursions; functions = joint stabilisation, force redistribution, elevator-muscle relaxation; maxillary Michigan for severe Class II/large overjet, mandibular Tanner for Class III, deep curve of Spee, less speech/visibility/airway impact. Lower: fabricate on arch with fewer missing teeth for stability, deprograms muscles for reproducible CR records in full-mouth reconstruction, can serve as a post-ortho retainer, wear facets removed at recalls to keep surface flat.
Apply thickness and coverage guidelines for splint fabrication. High-yield: muscle relaxation/bruxism more effective at 4.4–8.2 mm than 1 mm; disc displacement with reduction = 4 mm, without reduction = 6 mm; minimum 4 mm vertical thickness for strength; must cover all teeth including unerupted third molars in teenagers to prevent super-eruption. Lower: tooth-wear prevention needs only minimal material-dependent thickness, must seat firmly without rocking and not require active holding during sleep.
Compare hard vs soft appliances using the EMG evidence and define the soft-splint emergency role. High-yield: hard appliances significantly reduce nocturnal muscle activity (Okeson); soft appliances may increase masseter activity/maximum clenching on immediate insertion (Savabi et al.); soft splints reserved for short-term emergency pain relief only (maximum one week). Lower: soft contraindicated for long-term TMD management, hard remains the durable adjustable mainstay.
Explain the NTI / anterior bite plane premise and recognise its risks and duration limit. High-yield: engages only 2–4 maxillary incisors to disocclude posteriors and reduce noxious trigeminal feedback; maximum 3-month use due to risk of anterior open bite from posterior over-eruption / maxillary anterior intrusion; generally NOT advised. Lower: RCT showed no significant difference vs flat-plane appliance over 3 months (muscle tenderness, pain, opening, headache) and less effective than a stabilisation appliance, additional risks = tooth mobility and swallowing the small appliance.
Describe the anterior repositioning appliance, its indications in disc displacement, and its irreversible risks. High-yield: maxillary appliance with anterior guiding ramp + occlusal indentations locking the mandible forward; indicated for anterior disc displacement WITH reduction to “recapture”/reposition the condyle under the disc; short-term only — transition to a stabilisation appliance within ~3 months or risk permanent occlusal change. Lower: also used for acute retrodiscal oedema/trauma and chronic painful displacement to offload inflamed retrodiscal tissue, bimaxillary versions used in OSA to advance mandible/tongue, posterior bite plane (lower arch) risks posterior open bite and is not recommended in general practice, irreversible changes may need ortho/orthognathic correction.
Apply the fabrication, adjustment, recall and care workflow for a stabilisation splint. High-yield: bite registration at desired vertical dimension using a leaf gauge or Lucia jig (not closed-bite records); adjust to uniform centric contacts on all opposing teeth then eliminate excursive interferences (blue = static/centric, red = excursive); recall at 1–2 weeks then 3 months; clean with liquid soap and lukewarm water — NEVER toothpaste or hot water. Lower: digital scanning is the impression mainstay, troubleshoot instability/over-retention/looseness by remaking or selective grinding, weekly 15-min soak in dilute white vinegar/denture tablets, store away from sunlight and pets, patients never self-adjust and cracked splints need professional repair.
Recognise the idiopathic condylar resorption case lesson and the role of baseline records. High-yield: progressive condylar shortening causes posterior mandibular rotation and a new anterior open bite that can masquerade as a splint-induced occlusal shift; comparison with initial diagnostic casts/photos is what confirms a pathological (not appliance) change. Lower: MRI shows sclerotic/irregular condylar stump, may associate with juvenile idiopathic/psoriatic/rheumatoid arthritis and be asymptomatic; case = open bite developing ~4 months after a stabilisation splint despite confirmed early uniform occlusion.

L4: Occlusion, TMJ & Tooth Replacement

Define ideal occlusion and its assessment criteria (simultaneous tooth contact with condyles fully seated in the fossae, no interference with harmonious mandibular movement). High-yield: functional cusps (maxillary lingual + mandibular buccal) evenly distributed as stable vertical stops into opposing fossae, MIP coinciding with the seated condylar position, no excessive load on any single tooth, TMJs unstrained. Lower: glossary distinctions (articulation, line of occlusion, eccentric/monoplane/spherical occlusion), “Contemporary Fixed Prosthodontics” source wording.
Describe the clinical implications of occlusal disharmony and how each presents/is managed. High-yield: attrition (tooth-on-tooth wear, usually bruxism), anterior splaying from loss of posterior support/excessive anterior load, periodontal tenderness (PDL compression on percussion) and pulpal hypersensitivity from overload, occlusal fremitus/mobility with widened PDL but no apical radiolucency. Lower: re-check bite after recent restorations, numb patients failing full envelope of motion on articulating-paper checks, distinguishing PDL widening from infection.
Explain how occlusal overload contributes to cracked teeth and recurrent restoration failure (heavy loading on last teeth in the arch) — at the etiology level. High-yield: J Endod 2016 — lower 2nd molar most affected (25.1%), intact (34.3%) or Class I-restored (32.0%) teeth more affected, probing depth >6 mm a major negative prognostic factor (74.1% vs 96.8% survival <6 mm). Lower: peak age 50–60 (32.0%) and >60 (32.6%), 90% 2-year survival after RCT.
Describe TMJ anatomy and its ginglymoarthrodial (hinge + glide) motion. High-yield: components = condyle head, articular disc (dense connective tissue), glenoid fossa; rotation about the intra-condylar axis during initial opening (<2 cm), translation against the articular eminence on advanced opening (>2 cm). Lower: Dawson’s “Functional Occlusion” framework, disc–condyle assembly terminology.
Explain excursive mandibular movements and condylar guidance. High-yield: protrusion = both condyles glide forward; lateral excursion = working condyle rotates about a vertical axis within the fossa while the non-working condyle glides forward, downward and medially; condylar guidance/inclination set by the articular eminence. Lower: protrusion occurring in both horizontal and frontal planes, “guidance inclination” synonym.
Define the Bennett (side-shift) and Fisher angles and the components of lateral side shift. High-yield: Bennett angle ≈ 15° (sagittal plane vs advancing non-working condyle path, horizontal view); Fisher angle = between protrusive and lateral excursive paths (lateral path steeper). Lower: immediate vs progressive side shift, clinically replicated on an articulator to reflect patient jaw relationships, anterior (palatal of maxillary anteriors / labial of mandibular incisors) vs posterior (eminence + condyle) determinants.
Compare Centric Relation (CR) with Maximum Intercuspal Position (MIP) and when each is used. High-yield: MIP = best fit of teeth, independent of condylar position; CR = condyles anterior-superior against posterior slopes of eminences, tooth-independent, reproducible/unstrained, purely rotary; use CR for complete dentures (no existing MIP) or when changing the occlusal scheme (e.g. attrition), use MIP when restoring within the existing scheme. Lower: CR as a repeatable reference position, dynamic occlusion guided by TMJ + dentition.
Classify the occlusal schemes and recall the 5-point ideal-occlusion criteria checklist. High-yield: canine guidance (mutually protective, typical for dentate) vs group function (working-side group contact) vs bilateral balanced (edentate/complete dentures only — too destructive on natural teeth); checklist = mandibular stability, axial load, no working-side interference, non-working-side disocclusion, posterior disocclusion in protrusion. Lower: canine guidance contraindicated if canines endo/perio compromised, “dots in back/lines in front,” balanced needs ≥3 contacts (2 posterior + 1 anterior), 3 primary goals (stability, axial load, no interference).
Classify occlusal interferences by location. High-yield: centric, working, non-working, protrusive; interferences cause mandibular deviation on closure or hinder smooth movement to/from MIP. Lower: occlusal analysis as the assessment method, distinction from deflective contacts.
Explain the systemic impacts of tooth loss and residual ridge resorption patterns. High-yield: mandibular bone loss > maxillary, greater posteriorly than anteriorly — broadens the mandibular arch while constricting the maxillary arch; loss of functional stimulus drives unpredictable ridge volume loss (height + width) affecting future implant bone. Lower: weak/inconsistent evidence for nutritional deficits (Gaewkhiew, Geissler & Bates Hb/Vit C), missing molars → more chewing strokes + larger swallowing-threshold particles, chewing efficiency more linked to cognition than tooth count (Elsig), dentures may slow cognitive decline in partially dentate (Qi), life-course/childhood-cognition confounder (Thomson & Barak).
Apply the prosthetic-options hierarchy and shared decision-making to tooth replacement. High-yield: continuum from most to least natural = implant → tooth-supported fixed (FPD/bridge) → removable (RPD/denture); shared decision-making covers technical/physical, esthetic, maintenance/cost, and physiologic (“feel”/proprioception) outcomes. Lower: fixed replaces coronal portion rigidly vs removable replaces teeth + tissues, tooth loss as a non-reversible condition where managing expectations exceeds technical difficulty, etiologies (congenital, perio, caries, trauma, resection).
Describe immediate tooth-replacement options and the immediate-denture reline protocol. High-yield: options = suspension bridge/Essix (cheap, quick, cannot eat on it), immediate FPD, immediate denture (inserted day of extraction, lab estimates ridge contour so fit unpredictable, no try-in), immediate implant (placement + temp abutment/crown at extraction); keep denture in for the first 24 h to control swelling; direct relines until healing (~3 months bone remodeling) then indirect reline. Lower: rationale (aesthetics, function in full clearance, soft-tissue preservation), reline steps (roughen surface → apply material → bite in MIP → border mold → trim excess), immediate-implant soft-tissue review ~6 months.

Treatment Planning Resources

About this section

Drawn from Resources for Treatment Planning — the curated index of perio classification, prognosis, occlusion, endodontic-diagnosis, OCHWA clinic protocol, and materials summaries. Objective depth is weighted by exam yield: planning/diagnosis fundamentals, prognosis, perio staging, cracked-tooth management, and material/cement selection are given full treatment; supporting topics are condensed.

Planning Fundamentals, Sequencing & Decision-Making

Define treatment planning and state its rationale (a coordinated, proactive sequence of actions deciding what is done and when, built from history → assessment → diagnosis → problem list → options → prognosis). High-yield: the plan is a proactive coordinated sequence, NOT reactive, not fixed, not “item numbers on a page,” not finance-driven; core objectives = solve the patient’s problem(s), prioritise/sequence, build in preventive measures, estimate costs, secure consent, communicate with clinicians; it is a medico-legal requirement. Lower: terminology splitting management/treatment/sequence/procedure/step, “perfect station” vs real-world simplicity.
Sequence a comprehensive plan through the five Stefanac phases and state the goal of each (Systemic → Acute/urgent → Disease Control/stabilisation → Definitive/reconstructive → Maintenance). High-yield: order and purpose — Systemic (stabilise general health/medical risk before active dentistry), Acute (relieve pain, swelling, infection, trauma), Disease Control (arrest active caries/perio, caries removal, extractions, OHI before any definitive work), Definitive (crowns, dentures, RPDs, implants — only after disease controlled), Maintenance (recall/review, e.g. 6/12); disease MUST be controlled before reconstructive/definitive treatment begins. Lower: that DMD3 is when definitive-phase clinical work starts, episodic vs comprehensive-care patient profiles.
Explain the Systemic phase and how medical findings modify the plan (assess general health before active therapy; four aims = recognise undiagnosed disease, modify treatment, prevent medical emergencies, prevent complications). High-yield: ASA Physical Status I–IV (II = mild/controlled e.g. well-controlled DM/HTN, pregnancy, smoker; III–IV may need medical consult); key actions = physician consultation, postpone/limit treatment (defer elective care if BP ≥180/110 or unstable angina), stress/anxiety management (short AM appointments, sedation), medication changes incl. antibiotic prophylaxis, chair positioning (CCF/late-pregnancy/orthostatic hypotension); BP recorded every appointment. Lower: oral signs of systemic disease (erosion→GERD/bulimia, gingival hyperplasia, candidiasis), slow chair-raising rationale.
Distinguish an acute emergency from an urgent problem and outline acute-phase management aims. High-yield: emergency = incapacitating/potentially life-threatening, seen same-day (severe pain, spreading swelling, systemic infection, uncontrolled bleeding, facial/jaw trauma); urgent = should be done “now/soon” but can be palliated/postponed (mild–moderate pain, asymptomatic fracture, lost restoration, aesthetics); aims = resolve symptoms, preserve structures/limit spread, restore comfort/function/temporary aesthetics; abbreviated focused exam + SOAP documentation; NSAIDs preferred over opioids, antibiotics only with systemic involvement, with definitive follow-up scheduled. Lower: anxious patients perceiving all problems as urgent, acute care as a route to converting episodic patients to comprehensive care.
Apply patient-level risk assessment to anticipate future disease and tailor the plan (likelihood of developing/continuing a condition; modifiable vs non-modifiable factors; high/moderate/low grading). High-yield: previous disease experience is the strongest predictor of future disease; the dental team targets MODIFIABLE factors (diet, oral self-care, smoking) over non-modifiable (age, genetics); domain tools — caries (CAMBRA/Cariogram), perio, occlusal/bruxism, oral cancer (tobacco, alcohol, high-risk HPV); risk drives prognosis and intensity of prevention. Lower: risk indicator vs risk factor distinction, social determinants of health as modifiable rapport-building opportunities.
Explain shared decision-making and the elements of valid informed consent (the patient must accept they have a problem before accepting treatment; consent is a conversation, not just a form). High-yield: consent elements = diagnosis/prognosis, ALL reasonable options INCLUDING no treatment, risks/benefits of each, nature of recommended treatment, and costs — documented in the record; never assume consent carried over from a previous practitioner — always ask; give written plans with itemised fees in advance and allow time for questions. Lower: Health Belief Model (susceptibility, seriousness, benefits vs barriers, self-efficacy, cues to action), framing communication around tangible concerns (decay, bleeding, pain, gaps).
Justify presenting the ideal plan first, then deriving a modified plan from patient modifiers, and acting as a clinician rather than a salesperson. High-yield: always present the ideal treatment option first, THEN create a modified plan around patient modifiers (finances, motivation, fear, systemic health) — do not let finances dictate the clinical plan; avoid the “sales pitch,” act as a health professional, full disclosure of complications/prognosis as risk management. Lower: clinician-side modifiers (competence, experience, facilities, specialist access), thorough record-keeping for medico-legal protection.

History Taking & Communication

Describe the four core objectives of the clinical interview that frame every history (information gathering, establishing rapport, clinical reasoning, patient-centred care). High-yield: eliciting Ideas, Concerns and Expectations (ICE) as the patient-centred core, and that history exists both to gather data and to build the therapeutic relationship. Lower: developing shared beliefs and shared goals/processes from first contact.
Structure a complete medical-model history in correct sequence (patient profile → chief complaint → HPI → PMH → medications/allergies → family history → social history → review of systems). High-yield: the chief complaint then HPI ordering, and that the GDP “Components of History Taking” reduce to four — presenting complaint, history of presenting complaint, dental history, medical history. Lower: family history and full review-of-systems detail.
Elicit and characterise the presenting (chief) complaint and its history using open-then-closed questioning and the What/Why/Where/When/How probes. High-yield: classifying complaints by the Rosenstiel categories — Comfort, Function, Social, Appearance, and opening with open-ended questions before narrowing with closed ones. Lower: SOCRATES-style symptom probing, tailoring to language/communication barriers.
Explain the essential communication techniques that make a history effective (active listening, questioning style, non-verbal cues, signposting). High-yield: signposting transitions between history sections, open vs closed questioning roles, and active listening via verbal/non-verbal acknowledgement. Lower: sincerity, empathy, and individualising interaction to each patient.
Apply rapport-building and non-verbal strategies during the interview and adapt them for the upset, anxious, or in-pain patient. High-yield: sit at the patient’s level, maintain eye contact (eyes not just mouth), remove mask/gloves for the initial conversation, avoid being formulaic, and use supportive verbal openers (“How can I help you?”). Lower: small talk to relieve anxiety, opportunistic clinical observation (smile line, worn teeth, speech) during conversation.
Take a focused dental history and identify how it captures behavioural risk and treatment context. High-yield: attendance pattern, commitment, and quality/longevity of previous dentistry; specific items — orthodontics, wisdom teeth, dento-facial trauma. Lower: reliance on patient memory and obtaining previous records/previous dentist details.
Explain how the medical, medication, and social history screens for oral-disease risk and treatment-modifying conditions (using the OHCWA Form 1 structure). High-yield: the lifestyle risk factors — smoking, alcohol, drug use, diet plus medical co-morbidities — and that medications/allergies are systematically recorded. Lower: Form 1 system-by-system questionnaire categories (cardiovascular, respiratory, haematology, endocrine, allergies, pregnancy), re-evaluation/consent requirements.
Explain how the completed history feeds the problem list and the patient-centred factors that shape the plan. High-yield: history is the first input to the diagnostic chain (history → assessment/findings → diagnosis → problem list) and patient factors of attitudes/motivation, cost/finances, and maintenance drive plan acceptance. Lower: age, gender, and clinician relationship as modifying factors.

Clinical Examination & Diagnostic Steps

Perform a systematic extra-oral examination before entering the mouth (head/neck, face, smile, speech, asymmetry, swelling, midline, occlusal/incisal plane, facial type/profile). High-yield: visual plus palpation of TMJ, lymph nodes, thyroid, muscles of mastication and lips, each documented as NAD or with the abnormality named. Lower: facial-type/profile classification, smile-line aesthetics.
Perform a structured intra-oral soft-tissue examination by inspection and palpation of every site, alert to oral signs of systemic disease. High-yield: full site sequence — lips/vermillion, sulci, buccal mucosa, palate, tongue, floor of mouth, frena, ducts, saliva — and recognising manifestations (dry mouth from medications/diabetes, lichen planus, pemphigus, denture/nicotinic stomatitis). Lower: the dentist’s role in early systemic diagnosis as rationale.
Describe periodontal charting using a BPE/CPITN screen and its component measures. High-yield: probing pocket depth, recession, bleeding on probing, furcation involvement, mobility and marginal discrepancy as the recorded parameters. Lower: index history; charting tools (TOHM odontogram) that cannot be “locked”.
Apply a systematic hard-tissue charting sequence to examine teeth and existing restorations. High-yield: quadrant order Q1→2→3→4, dry teeth with triple syringe, mirror + sickle probe, percussion (TTP), caries screen; routinely overlooked buccal of upper molars and lingual of lower molars. Lower: charting in eform documentation.
Evaluate the quality and material of existing restorations and prostheses to judge satisfactory vs unsatisfactory. High-yield: margins/marginal integrity, overhangs, contour, proximal contacts, shade and associated gingival health; replacement criteria = defective margins/leakage/fracture/wear, caries, poor contour, aesthetic failure. Lower: GIC-vs-composite differentiation (gingival third + porous surface), denture retention/support/stability assessment.
Perform occlusal assessment of both static and dynamic relationships using articulating paper. High-yield: static contacts in maximum intercuspation (MIP) vs dynamic contacts in excursive/protrusive movements; location of marks on marginal ridges, cuspal inclines, transverse ridges and grooves guides restoration. Lower: articulator/study-model mounting.
Select special diagnostic tests to supplement the clinical exam, taking radiographs only when clinically justified. High-yield: pulp sensibility testing at the new-patient exam (cold/thermal and EPT), radiographs only when clinically necessary, plus cracked-tooth tests and pain-on-biting history. Lower: articulated study models, clinical photographs, plaque scores.
Apply diet and saliva analysis for caries-risk data-gathering. High-yield: a diet diary for cariogenic-intake assessment; Saliva-Check parameters — hydration, viscosity, resting pH 5.0–5.8, stimulated quantity, buffering — flag high caries risk. Lower: resting vs stimulated saliva distinction, bicarbonate basis of buffering.

Diagnosis & Problem List

Synthesise history, clinical examination, and special-test findings into a coherent diagnosis, recognising that the diagnostic process is iterative (patients return with added clarity/history, and a “cooling-off period” refines the picture). High-yield: special tests confirm/verify clinical findings and support the final diagnosis, the decision to test is gated by how much NEW information is gained. Lower: documentation rationale, iatrogenic-test caveats.
Distinguish the tiers of diagnosis and choose the correct label for a scenario — provisional/tentative (working clinical impression, pre-investigation), differential (ranked list of plausible causes), and definitive (single most-likely diagnosis after tests narrow possibilities). High-yield: provisional = a “cracked tooth” impression before confirmatory testing, differential = list differing by ≥1 feature, definitive often unattainable when no disease-specific test exists. Lower: synonym “tentative”.
Describe how the structured problem list is built — a summary of complaints, lesions, and conditions warranting further evaluation or treatment, derived directly from examination observations (e.g. restoration overhangs, marginal deficiencies, caries). High-yield: the problem list flows FROM observations not assumptions, each problem must trace to a finding, and the patient’s CHIEF COMPLAINT must be captured as a problem (not just incidental disease). Lower: limited diagnosis text fields in software.
Apply a categorisation scheme to organise problems — by acute vs chronic (recent symptomatology vs long-standing/radiographically evident) and by discipline (perio, endo, restorative, prosthetic, occlusal). High-yield: acute = recent symptoms, chronic = longstanding/visible on radiograph, emergency problems (pain, swelling, systemic infection, trauma) flagged as immediate. Lower: medical vs dental split.
Prioritise problems into a clinically defensible order so the list drives, rather than follows, decision-making. High-yield: sequence = chief complaint first, then current medical conditions, then general dental problems, then specific dental lesions, prioritised by clinician judgement of urgency/risk. Lower: re-ordering as new findings emerge.
Explain how the diagnosis and problem list feed forward into the treatment plan — each prioritised problem maps to a management decision, with the patient’s primary complaint addressed rather than focusing solely on disease control. High-yield: the problem list is the bridge from diagnosis to plan, address the chief complaint explicitly, discuss treatment and rare-complication risks with the patient. Lower: separate follow-up appointments and written correspondence for complex plans.

Tooth Prognosis & Restorability

Classify individual-tooth prognosis using the Samet & Jotkowitz comprehensive system (Quintessence Int 2009; each tooth graded against four criteria, single most severe criterion sets the class). High-yield: five classes A–X — A Good, B Fair, C Questionable, D Compromised, X Nonsalvageable/extract; four criteria = periodontal support, restorability (remaining sound structure + ferrule), endodontic condition, occlusal plane/position; the worst criterion alone dictates the class. Lower: developed as a standardized prosthodontic treatment-planning aid, distinct from McGuire & Nunn’s purely periodontal 1996 system.
Apply the three-step scoring logic that converts findings into a final grade (Step 1 base class, Step 2 tooth-level drop, Step 3 patient-level drop). High-yield: Step 1 = each criterion scored both as-presented and as-foreseen after caries removal, worst sets base class; Step 2 = anatomic or iatrogenic factors drop one class (more than two findings drop further); Step 3 = considerable patient risk drops all teeth one class, re-raised when modifiable factors improve. Lower: class can be raised again over time on review as risk is controlled.
Apply the periodontal criterion across the five classes by bone support, maintainability, and furcation. High-yield: A = 80–100% bone, easily maintained; B = 50–80%, maintainable with rigorous therapy; C = 30–50%, cleansability difficult; D = <30% with active disease; X = <30% with unavoidable acute outbreaks; PPD ≤3 mm/BoP−/PAL loss ≤25%/FI ≤I = good vs PPD ≥6 mm/BoP+/~50% PAL loss/FI II–III = questionable. Lower: molars carry higher risk than single-rooted teeth at the same bone level; corroborated by McGuire & Nunn (>75% bone loss, Grade III mobility, untreatable Class III furcation, attachment within 3 mm of apex = hopeless).
Apply the restorability criterion using remaining sound coronal structure, ferrule, and crown-to-root ratio. High-yield: A = 80–100% sound structure with adequate ferrule; B = 50–80%, restorable without biologic-width infringement; C = 30–50%, ferrule only by compromising crown–root ratio/adjacent structures; D = <30%, ferrule unachievable; X = no supragingival sound structure, loss deep into root/canals; ferrule ≈1.5–2 mm of 360° sound circumferential dentin above margin (~4 mm wall height, 15–20° convergence) is the restorability threshold. Lower: crown-to-root ratio 1:2 ideal, 1:1.5 acceptable, 1:1 the limit; restorability driven by FEA/fracture-resistance evidence on post-restored teeth.
Apply the endodontic criterion by predictability of primary or retreatment therapy. High-yield: A = straightforward primary RCT or sound existing therapy; B = failing RCT with obvious cause, predictably retreatable, or difficult primary RCT; C = acute/chronic failing RCT hard to retreat predictably; D = failing RCT not predictably retreatable; X = vertical root fracture, or repeatedly retreated (endo + surgical) without resolution. Lower: symptomatic tooth with an untreatable radiolucency falls to hopeless on this criterion alone.
Apply the occlusal plane/position criterion to grade malposition and post-treatment crown-root outcome. High-yield: A = correct plane or slight deviation needing minimal enameloplasty; B = out of plane but adjustable to function; C = out of plane requiring multiple procedures; D = so tilted that post-treatment crown–root ratio prevents long-term service or position harms neighbours; X = super-erupted/tilted beyond restoration or blocking opposing-arch restoration. Lower: this is the least commonly examined of the four criteria but completes the worst-criterion rule.
Apply the Step-2 modifiers that drop a tooth a class regardless of base grade (anatomic and iatrogenic risk). High-yield: anatomic = thin/short/conical roots, multiple canals/roots; iatrogenic = perforations, extensive posts, minimal residual wall thickness, non-removable materials; either drops one class and may indicate extraction once further treatment is planned. Lower: an iatrogenically compromised tooth may sit asymptomatic at fair/good until intervention or new symptoms appear.
Explain Step-3 patient-level modifiers that shift the whole dentition (biologic, behavioural, financial). High-yield: biologic = impaired healing/immunity, reduced salivary flow, high S. mutans/Lactobacillus, IL-1 genotype; behavioural = poor hygiene, cariogenic diet, parafunction, smoking, non-adherence; financial/personal = motivation, resources, dental IQ, esthetic expectations; considerable risk drops all teeth one class. Lower: reassessed longitudinally — drop further if uncontrolled, raise when modifiable factors clearly improve.
Explain how class drives the keep-versus-extract decision and abutment selection (D vs X is the pivotal distinction). High-yield: X = active indication for extraction (nonsalvageable) whereas D = no active indication — patient/external factors decide whether to invest; a tooth re-graded C or D is usually unsuitable as a planned bridge abutment, prompting an alternative plan, though patient goals/finances may justify retaining it as an interim individual unit. Lower: esthetics influence the treatment choice but do not alter the tooth’s intrinsic prognosis.

Periodontitis Staging and Grading

State the components of a complete periodontitis diagnosis and the umbrella-term shift of the 2018 (2017 World Workshop) classification (replacing chronic/aggressive categories). High-yield: Stage (I–IV) + Extent/distribution + Grade (A/B/C), written as e.g. “Generalised Stage III, Grade B”; single “periodontitis” diagnosis now replaces “chronic” and “aggressive”. Lower: necrotising periodontal diseases and periodontitis as a manifestation of systemic disease remain separate categories, framework from Tonetti/Greenwell/Kornman 2018 + Papapanou consensus.
Stage periodontitis by severity, anchoring the initial stage on interdental clinical attachment loss at the worst site (RBL as fallback). High-yield: set initial stage from interdental CAL at worst site — Stage I 1–2 mm, II 3–4 mm, III ≥5 mm, IV ≥5 mm; RBL — I coronal third (<15%), II coronal third (15–33%), III/IV mid or apical third. Lower: CAL preferred over pocketing/RBL due to low specificity of the latter, use RBL only when CAL unavailable.
Apply tooth-loss and complexity factors to shift the stage upward, distinguishing Stage III from IV. High-yield: tooth loss (perio cause) — I/II none, III ≤4 teeth, IV ≥5 teeth; max probing depth I ≤4 mm, II ≤5 mm, III/IV ≥6 mm; vertical bone loss ≥3 mm, Class II/III furcation, and ridge defects flag ≥ Stage III; III→IV driven by complexity (masticatory dysfunction, secondary occlusal trauma with mobility ≥ degree 2, bite collapse/drifting/flaring, <20 remaining teeth = <10 opposing pairs). Lower: ridge defect moderate (III) vs severe (IV), “need for complex rehab” is Stage IV–only descriptor.
Explain the “highest qualifying feature” rule for assigning stage. High-yield: stage = the single highest qualifying severity OR complexity feature — one factor sets the stage (e.g. Class II/III furcation alone → ≥ Stage III regardless of CAL); not all factors need be present. Lower: use clinical judgement on borderline cases.
Classify the extent/distribution descriptor that accompanies the stage. High-yield: localised (<30% of teeth), generalised (≥30%), or molar–incisor pattern. Lower: descriptor applies across all stages, sits between Stage and Grade in the written diagnosis.
Grade periodontitis to estimate progression rate, starting every case at Grade B and using direct evidence when available. High-yield: start at Grade B, shift on evidence; direct evidence (longitudinal RBL/CAL over 5 yrs) — A no loss, B <2 mm, C ≥2 mm; A slow / B moderate / C rapid. Lower: grade reflects future-progression risk and likelihood of poor outcomes, assessed at worst-affected tooth.
Apply the indirect grading method (%RBL ÷ age) when longitudinal data are absent, including how to measure %RBL. High-yield: %bone loss ÷ age — <0.25 = A, 0.25–1.0 = B, >1.0 = C; measure RBL ~2 mm below CEJ to bone crest as a fraction of total root length at worst tooth (e.g. 30% at age 60 = 0.5 → B; 30% at age 25 = 1.2 → C). Lower: case phenotype — C shows destruction exceeding biofilm, molar/incisor or early-onset pattern, poor response to standard therapy.
Apply smoking and diabetes grade modifiers, which only raise the grade. High-yield: smoking — non-smoker (A), <10 cig/day (B), ≥10 cig/day (C); diabetes — normoglycaemic (A), HbA1c <7.0% (B), HbA1c ≥7.0% (C); a Grade A/B case with ≥10 cig/day or HbA1c ≥7.0% becomes Grade C. Lower: modifiers move grade upward only, applied after direct/indirect evidence sets the baseline.
Describe how stage and grade behave after treatment (the “stage doesn’t go down” rule). High-yield: stage does not regress with treatment — if therapy eliminates a stage-shifting complexity factor, carry the original complexity into maintenance planning; CAL and RBL remain primary determinants post-treatment. Lower: stable treated patients retain their highest historical stage for ongoing risk stratification.
Sequence non-surgical periodontal therapy through the staged-treatment workflow with re-evaluation and referral. High-yield: OHI → scaling/root planing (SRP) → risk-factor control (smoking cessation, glycaemic control) → re-evaluate, then refer; Step 1 behaviour change/risk-factor control, Step 2 subgingival instrumentation (NSPT), Step 3 surgical management of residual pockets, Step 4 supportive maintenance. Lower: re-evaluate response before escalating; refer Stage III/IV or non-responders for surgical/specialist care.

Periodontal Health and Gingival Diseases

Define periodontal/gingival health (2017 World Workshop, workgroup 1) as the absence of clinically detectable inflammation, distinguishing an intact from a reduced periodontium. High-yield: health = BoP <10% of sites, PPD ≤3 mm, no attachment/bone loss; intact periodontium has physiological bone 1.0–3.0 mm apical to the CEJ. Lower: health reflects immune surveillance/homeostasis, not sterility.
Apply the gingivitis case definition on an intact (or reduced non-periodontitis) periodontium (plaque-induced inflammation diagnosed clinically). High-yield: gingivitis = BoP ≥10% of sites with PPD ≤3 mm; localised 10–30%, generalised >30% bleeding sites; probe 6 sites/tooth at ~0.2–0.25 N. Lower: gingivitis is a clinical diagnosis (erythema, edema, papilla blunting), radiographs cannot diagnose it.
Differentiate dental-biofilm-induced gingivitis from non-plaque-induced gingival diseases (etiology and response to plaque removal). High-yield: plaque-induced resolves with biofilm removal; non-plaque-induced does NOT — genetic/developmental, infections, immune/inflammatory, reactive, neoplasms, nutritional/metabolic, traumatic, pigmentation. Lower: non-plaque-induced may be local or a systemic manifestation, severity still modifiable by superimposed plaque.
Classify the reduced periodontium into its two patient types and explain why a treated periodontitis patient achieves “gingival health on a reduced periodontium,” NOT health. High-yield: non-periodontitis (recession, post-crown-lengthening — no increased risk) vs successfully treated stable periodontitis (lifelong recurrence risk, needs monitoring); a periodontitis patient with inflammation is still a periodontitis patient. Lower: bone loss persists permanently regardless of inflammatory status.
Contrast the diagnostic thresholds for a stable treated periodontitis patient against an intact periodontium (pocket-closure logic). High-yield: stable health = BoP <10%, PPD ≤4 mm with no ≥4 mm site bleeding; gingivitis threshold drops to a bleeding site ≤3 mm due to recurrence risk; a bleeding PPD ≥4 mm is no longer a “closed pocket.” Lower: severity terms (mild/moderate/severe) are for communication only, no objective criteria.

Periodontal Abscesses and Necrotizing Periodontal Diseases

Describe the periodontal abscess and its etiology (localized pus in the gingival wall of a pocket, 2018 classification by setting). High-yield: in periodontitis patients = acute exacerbation of a pre-existing pocket (untreated/refractory disease, during maintenance) or post-treatment (post-SRP dislodged calculus, retained foreign bodies, antibiotics without debridement); in non-periodontitis patients no pocket required — impaction (floss, orthodontic elastic, popcorn hulls), root alterations. Lower: drug-related (nifedipine), harmful habits, orthodontic forces, cross-bite.
Diagnose the periodontal abscess from its presentation (rapid-onset localized swelling). High-yield: pain, tenderness, tooth “elevation”, ovoid lateral swelling pointing along the root, suppuration on probing (66–93%), deep pocket ~7–9 mm with bleeding on probing (~100%) and mobility; diagnosis is clinical. Lower: radiographic bone loss usual, fistula uncommon, extraoral signs (fever, lymphadenopathy) flag systemic spread.
Manage the acute periodontal abscess (emergency-phase priority). High-yield: establish drainage (through pocket or incision) plus debridement of pocket/root surface; systemic antimicrobials only with spreading infection or systemic involvement. Lower: address underlying etiology (foreign body, perforation), then definitive periodontal therapy.
Describe the necrotizing periodontal disease spectrum and its classic triad (NG–NP–NS as stages of one process). High-yield: triad = painful punched-out/ulcerated interdental papillae, gingival bleeding, necrosis/pseudomembrane; NG = no attachment loss, NP = adds attachment + alveolar bone loss, NS = adds bone denudation through mucosa with sequestrum; spirochetes + fusiform bacteria driven by compromised host. Lower: halitosis, adenopathy/fever, NS in severely compromised only.
Differentiate NPD predisposing factors and host status (immune-driven severity). High-yield: smoking, stress, immunosuppression (HIV/AIDS, CD4 < 200), malnutrition; new-onset NPD without cause warrants immunosuppression screening; differentiate from herpetic gingivostomatitis and vesiculobullous disease. Lower: children — measles/herpesvirus infections, extreme living conditions; residual craters, tooth malposition/root proximity.
Manage necrotizing periodontal diseases (acute then cause-directed). High-yield: gentle superficial debridement of necrotic tissue (avoid aggressive instrumentation acutely), reinforce oral hygiene and pain control, manage predisposing factors; add metronidazole only with systemic signs (fever, lymphadenopathy). Lower: definitive periodontal correction of craters after resolution.

Endo-Periodontal Lesions

Define an endo-periodontal lesion as a pathological communication between the pulp and periodontium of one tooth (acute or chronic, involving both compartments). High-yield: communication via apical foramen, lateral/accessory canals (apical third, furcation), dentinal tubules; no specific microbiology — shared anaerobic flora. Lower: red/orange-complex species (P. gingivalis, T. forsythia, P. micra, Fusobacterium, Treponema).
Classify EPL per the 2018 Herrera/World Workshop scheme by present disease status rather than origin, splitting on root damage. High-yield: with root damage = root fracture/cracking, perforation, external resorption (prognosis poor–hopeless); without root damage subdivided by periodontitis vs non-periodontitis patient. Lower: abandons older 1999/Simon origin-based schemes.
Classify EPL without root damage by extent (grading within periodontitis and non-periodontitis patients). High-yield: Grade 1 = narrow deep pocket, 1 surface; Grade 2 = wide deep pocket, 1 surface; Grade 3 = deep pockets >1 surface; prognosis better in non-periodontitis than periodontitis patients. Lower: non-periodontitis single lesions often linked to palatal/radicular grooves.
Diagnose EPL through staged history, radiographs, and periodontal–pulpal assessment, with pulp vitality testing pivotal. High-yield: deep pocket reaching/near apex + altered/absent pulp response (~100% of cases) indicates EPL; radiographs assess fracture/perforation/resorption. Lower: percussion adjunct, radicular groove mimics vertical root fracture, history of trauma/instrumentation/post.
Explain prognosis and treatment sequence by grade and root damage. High-yield: endodontic treatment first, then periodontal therapy for lesions without root damage; root damage → poor/hopeless, often extraction. Lower: furcation involvement, high bone loss, and grooves worsen prognosis; three prognostic groups (hopeless, poor–favourable).

Peri-Implant Diseases and Conditions

Define peri-implant health and mucositis and distinguish them clinically (2017 World Workshop, workgroup 4; reversible soft-tissue inflammation vs progressive bone loss). High-yield: peri-implant mucositis = BoP with no bone loss beyond initial remodelling (reversible); peri-implantitis = BoP/suppuration + progressive radiographic bone loss + increasing probing depth; health = no BoP/erythema/suppuration. Lower: lack of keratinised mucosa and absence of a fixed reference point complicate probing.
Recognise the risk factors and the prevention/maintenance imperative for peri-implant disease. High-yield: history of periodontitis, poor plaque control, and no regular maintenance are the key risk factors; mucositis precedes peri-implantitis so supportive peri-implant maintenance + biofilm control is the primary prevention. Lower: residual sub-mucosal cement, smoking, diabetes, malpositioned implants, occlusal overload as contributing factors.
Apply the diagnostic and management essentials, including baseline records. High-yield: a baseline radiograph + probing depths at prosthesis delivery are essential to detect later bone loss; mucositis → non-surgical debridement + OHI, peri-implantitis → refer for surgical/decontamination management. Lower: peri-implant soft- and hard-tissue deficiencies (ridge resorption, recession) addressed by grafting before or during placement.

Periodontal Soft-Tissue Root Coverage Procedures

Classify gingival recession and identify when root coverage is indicated (AAP Regeneration Workshop; Cairo recession-type system predicts coverage). High-yield: Cairo RT1 (no interproximal loss) = full root coverage predictable; RT2 (interproximal loss ≤ buccal) = partial; RT3 = coverage not achievable; indications = aesthetics, dentine hypersensitivity, cervical caries/abrasion, and to gain keratinised tissue. Lower: older Miller Classes I–IV map roughly onto the Cairo types.
Select the procedure and justify the role of graft thickness and keratinised tissue. High-yield: coronally advanced flap (CAF) + sub-epithelial connective-tissue graft (CTG) is the gold standard for predictable root coverage and gain of keratinised tissue; greater graft thickness (≈ ≥1 mm) improves complete-coverage outcomes; ≥2 mm keratinised tissue aids long-term stability. Lower: alternatives = acellular dermal matrix, enamel-matrix derivative, and free gingival grafts (better tissue gain, poorer colour match).

OCHWA Periodontal Treatment Protocol

Sequence the OCHWA phased periodontal workflow end-to-end (Steps 0–4, each gated by the Step 2B re-evaluation). High-yield: Step 0 emergency → Step 1 systemic/risk-factor → Step 2A non-surgical instrumentation → Step 2B re-evaluation at 8 weeks → Step 3 corrective/surgical vs Step 4 SPC, re-evaluation is the decision gate splitting maintenance from referral. Lower: protocol is OCHWA/UWA DMD-specific, discipline lead Dr Pradeep Koppolu.
Describe baseline charting and examination feeding diagnosis (history, radiography, EO/IO/perio exam). High-yield: periodontal chart in Titanium (Perio tab, includes plaque index + marginal bleeding), Periodontics eForm, item 221 clinical periodontal analysis and recording. Lower: comprehensive workup culminates in diagnosis.
Apply the probing comfort escalation ladder. High-yield: (1) probe all sites with no anaesthesia, (2) topical (Xylonor 10% spray/gel), (3) LA injection as last resort, aim to complete in a single session. Lower: discomfort-driven stepwise escalation.
Explain Step 0 emergency care for acute pain/infection. High-yield: acute periodontal abscess, necrotising periodontal disease, irreversible pulpitis; codes 213 acute periodontal infection, 013 limited exam, 419 extirpation/RCT debridement, 311/324 extraction. Lower: per-appointment billing for 213.
Explain Step 1 systemic/risk-factor control with supragingival biofilm removal only. High-yield: OHI (reinforced at all stages), smoking cessation (Ask–Advise–Help), diabetes control; codes 111 plaque/stain, 114 calculus first appt / 115 subsequent, 141 OHI, 142 tobacco, 131 dietary; never combine 111 with 114/115 (111 is included in them). Lower: 113 recontour/polish per tooth, extract asymptomatic hopeless teeth.
Explain Step 2A cause-related non-surgical (subgingival) instrumentation for all perio patients. High-yield: hand and/or powered instruments, quadrant-wise or full-mouth, to remove subgingival biofilm/calculus; codes 222 periodontal debridement (per tooth) and 250 active non-surgical therapy (per quadrant — ≥3 teeth with CAL ≥3 mm or PD ≥4 mm). Lower: chlorhexidine rinse as a time-limited adjunct, gross caries control, peri-implant disease → refer Periodontal dept.
Apply the Step 2B re-evaluation timing and success endpoints. High-yield: re-evaluate at 8 weeks; endpoints = no pockets ≥5 mm with BOP, no pockets ≥6 mm, full-mouth bleeding ≤20%; codes 221 + 022 radiograph; met → Step 4 (SPC + restorative/prosthetic), not met → Step 3. Lower: re-charting drives the branch decision.
Apply Step 3 corrective decision points and the referral thresholds. High-yield: 4–5 mm residual → repeat non-surgical instrumentation; ≥6 mm → surgical, refer Periodontal dept; localised (<30% sites) re-instrument by DMD, generalised (>30% sites) → refer; unclear cause → refer; codes 222, 250, 019 referral. Lower: peri-implant disease → refer; don’t defer to next year’s students.
Describe Step 4 supportive periodontal care (maintenance). High-yield: SPC recall 3–12 months, interval set by perio risk assessment tool (perio-tools.com/pra); PMPR + individually tailored OHI; bills Step 1 codes. Lower: lifelong patient-dependent maintenance after endpoints achieved.

Endodontic Diagnoses (Pulpal & Periapical)

Construct a complete endodontic diagnosis naming all four required elements (tooth identity, pulp/root-canal status, periapical/periradicular status, cause) — a healthy tissue must still be stated explicitly, never assumed. High-yield: four-part diagnosis (tooth + pulp + periapex + cause), “clinically normal” is a positive statement not silence, conditions are dynamic (pulpitis→necrosis→pulpless/infected; periapex cycles acute↔chronic). Lower: “clinically normal” ≠ histologically normal, Abbott classification origin (Ingle’s Tables 8-1/8-2).
Diagnose pulp status from sensibility (cold/EPT) plus symptom history, percussion, and radiograph (normal, reversible, irreversible, necrosis, previously treated) — sensibility response drives whether endodontics is needed first. High-yield: non-lingering response = vital/reversible, lingering/exaggerated response = irreversible, no response = necrosis (or calcified/false-negative), percussion tenderness signals periapical involvement. Lower: EPT tests nerve not blood supply (false positives/negatives), atrophy and calcification reduce test reliability.
Differentiate reversible from irreversible pulpitis on pain quality, duration, and trigger threshold (reversible vs irreversible, each acute/chronic) — lingering and/or spontaneous pain = irreversible. High-yield: reversible = sharp, short (seconds), needs extreme temperature, no lingering; irreversible = lingers >5 min on minor trigger, dull ache, spontaneous/nocturnal/worse lying down; acute = recent+consistent, chronic = long-standing+occasional. Lower: reversible is a provisional diagnosis confirmed only once symptoms resolve, cracked cusp can mimic reversible pulpitis.
Recognise the necrosis sequence and the “silent necrosis” pitfall (necrobiosis/partial → necrotic without infection → necrotic and infected → pulpless and infected) — sudden disappearance of sharp pain may mean the pulp has died, so re-test vitality. High-yield: necrobiosis = mixed pulpitis + infection symptoms (iced-water swishing may relieve), necrosis-without-infection follows trauma with no coronal bacterial pathway (no apical periodontitis), pulpless+infected once a periapical radiolucency appears. Lower: necrotic-and-infected is a brief transitional stage, partial necrosis gives mixed/inconclusive pulp-test results.
Classify previously treated teeth and pulp-space degenerative changes separately (previous RCT adequate/inadequate ± infected, pulp canal calcification, pulp hyperplasia/polyp, atrophy) — a radiolucency on a treated tooth means the canal is infected. High-yield: previously treated = note technical standard (adequate vs inadequate) and infection status, radiolucency present = infected RCS, PCC = narrowed/invisible canal (still diagnose underlying pulp state), pulp polyp = a form of irreversible pulpitis. Lower: “PCC” preferred over “obliteration” (a micro-canal always remains), atrophy is physiologic ageing, specify perforation/blocked canal/separated file.
Diagnose periapical/periradicular status across the full taxonomy (normal, acute/chronic apical periodontitis, condensing osteitis, acute/chronic apical abscess, cellulitis, cyst, scar) — pus and swelling separate abscess from periodontitis, radiolucency presence separates primary from secondary. High-yield: AAP = severe pain, no pus; abscess = pus ± rapid swelling, primary acute = no radiolucency (bone not yet resorbed), secondary acute = acute symptoms ON a pre-existing radiolucency, chronic = radiolucency ± minimal symptoms. Lower: foreign-body reaction/pocket cyst/true cyst/scar all give persistent post-RCT radiolucency separable only histologically, periapical scar is fibrous healing (not disease).
Interpret the radiograph as the central but lagging discriminator — radiolucency takes several months to appear, so its absence never rules out infection; it only means none was visible on that film. High-yield: absence of radiolucency ≠ absence of infection, draining sinus = chronic apical abscess (trace with GP point), radiopacity = condensing osteitis (pulp often still vital), narrowed/invisible canal = PCC. Lower: condensing osteitis ties to long-standing chronic reversible pulpitis, widened PDL is an early/equivocal sign, cysts and foreign-body reaction need histology.
Recognise facial cellulitis as the diagnosis demanding urgent escalation (spreading fascial-plane infection from a periapical abscess) — spreading swelling + fever/malaise = airway risk, not a “wait-and-see.” High-yield: spreading facial swelling, fever, unwell, lymphadenopathy → cellulitis, potential airway compromise, needs urgent active dental treatment (drainage/extirpation) not antibiotics alone. Lower: evolves from acute apical abscess, no response to pulp testing, radiolucency may or may not be visible.

How to Treat Cracked Teeth

Classify the cracked-tooth spectrum and pick treat-vs-extract per type (5 categories, GDP exam favourite). High-yield: craze lines = reassure/monitor only, fractured cusp = remove segment + cuspal coverage, cracked tooth = the key problem (out of occlusion → crown, RCT only if pulp fails), split tooth = extract (or hemisection if multi-rooted), VRF = single-rooted extract / multi-rooted resect. Lower: craze = enamel-only infractions, fractured-cusp pulp usually unaffected.
Apply the governing rule to every management decision (one-line exam mnemonic). High-yield: not all cracked teeth need RCT, but ALL cracked teeth need a crown — cuspal coverage drives prognosis. Lower: protocol shifted over last 15 yr toward reducing repetitive load and protecting tooth early.
Sequence the symptomatic cracked tooth’s first visit (irreversible-pulpitis SAQ opener). High-yield: take out of occlusion immediately (~2 mm reduction), chew contralaterally, provisional stabilise (temp crown/band, observe symptom resolution) before definitive crown. Lower: repetitive bruxing/grinding propagates crack toward fracture.
Manage the reversible-pulpitis cracked tooth without RCT (vital tooth → restore). High-yield: early cuspal coverage = bonded composite overlay, onlay, or full crown; immediately crowned reversible-pulpitis teeth had ~80% chance of never needing RCT, early crown improves prognosis ~98% over 11 yr. Lower: leave well-fitted temp until symptoms subside, then convert to definitive.
Sequence the irreversible-pulpitis / necrotic cracked tooth (the GDP-flagged scenario). High-yield: RCT first THEN cuspal-coverage crown (not extraction by default — RCT survival ~84% at 60 mo); place crown ASAP after RCT; RCT can be done through an existing crown and access restored. Lower: extract only if non-restorable or crack extends into root.
Explain the orifice-barrier step after obturation (reinforce + seal the crack). High-yield: place orifice barriers down to deepest visible crack extent under microscope; Davis & Shariff protocol (barriers + out of occlusion + 6-month recall) = 97% survival at 4 yr. Lower: seals against bacterial penetration, reinforces root.
Apply the Iowa Staging Index to set prognosis and the treat-vs-extract threshold (counsel patient). High-yield: probing depth < 5 mm favours treatment, ≥ 5 mm pushes extraction; Stage 1 (<5 mm, mesial ridge, no apical pathosis) 93% → Stage 4 (≥5 mm) 41%. Lower: distal marginal-ridge cracks fare worse than mesial; apical pathosis lowers success; backed by 2 meta-analyses.
Manage vertical root fractures by root number (resection options, often refer). High-yield: single-rooted → extract (no reliable treatment), multi-rooted → remove fractured root, restore sound root(s) — root amputation ~92% survival/12 yr, hemisection ~79–91%. Lower: endo-treated teeth with posts/over-instrumentation at greatest risk; resective procedures may need specialist referral.
Weigh tooth preservation against a single-tooth implant (informed-consent economics). High-yield: compromised natural teeth may outlast the average implant; an implant is ~4× appointments, ~2× cost of RCT + crown for equivalent success; preserve natural dentition to preserve bone. Lower: applies where a documented resective option exists.
Communicate the guarded prognosis and obtain informed consent (a crack is a structural “time bomb”). High-yield: warn the crack may still propagate, treatment buys time not a guarantee; mandate strict ~6-month recall with ongoing occlusal monitoring (integral to the survival figures). Lower: prognosis worsens with deeper probing, distal cracks, and apical pathosis.

OCHWA Endodontic Guidelines

Sequence the three-appointment OCHWA RCT workflow (examination/diagnosis/stabilisation → preparation → filling, ≥4-week intervals). High-yield: appointment 1 = diagnose + medicament + interim restoration, appointment 2 = working length + cleaning/shaping at same visit, appointment 3 = obturation; LA used until preparation is complete, contraindicated at the filling visit (masks perforation, residual pulp, over-long WL). Lower: Form 70 mandatory for all cases, Forms 71/72 treatment records, ADA codes 019/022/221, 3D’s of post-op pain.
Describe OCHWA case assessment and diagnosis (Form 70 endodontic exam, the four-part diagnosis). High-yield: note all four — tooth (FDI), pulp/canal state, periapical state, and CAUSE (bacterial entry pathway); sensibility testing (CO₂ + EPT), transillumination, modified-parallel radiographs with RINN XCP ± tube-shift; remove all restorations/caries/cracks to confirm restorability before consent. Lower: informed consent that feasibility is RCT-or-extract, #331 Jet bur for access, DG16 orifice probe.
Apply the UWA irrigation protocol across filing, disinfection and final flush. High-yield: EDTAC 15% during ALL filing (lubricates, removes inorganic smear — never NaOCl while filing), then NaOCl 1% after enlargement to dissolve organic tissue (flush, hold 30–60 s, ≥5 min, agitate with size-15 file), then EDTAC final flush 2–3 min; closed-ended needle near WL, exchange zone only 1–1.5 mm past tip. Lower: Elkholy guide uses 2.5% NaOCl throughout rotary, EDTAC-only at the filling visit.
Explain intracanal medicament selection and timing by diagnosis. High-yield: irreversible pulpitis/elective → 50:50 Ledermix + Ca(OH)₂; necrotic/infected/pulpless/root-filled → Ca(OH)₂ alone (Pulpdent); place with spiral filler 3–4 mm short of WL, keep in canal only; Ca(OH)₂ optimal 1–2 weeks, avoid >1 month (collagen degradation/root-fracture risk). Lower: initial-visit medicaments (Ledermix for pulpitis, 50:50 for necrotic), double-layer Cavit + hand-mixed IRM temporary.
Sequence the ProTaper Ultimate preparation and obturation. High-yield: crown-down scout (08/10 K-file) → SX orifice opener → Slider/Shaper → patency → glide path to size 15 → Slider → Shaper → F1 → F2 (F3 if gauging) with NaOCl + patency between files; obturate with gutta-percha + sealer, master cone matched to final prep with tug-back 0.5–1 mm from apex; single cone for hydraulic calcium-silicate sealers, lateral condensation (D11 spreader, accessory points) for resin AH Plus/AH26. Lower: rotary safety (light pecking, “just kiss the apex”), Hedström hand-prep minimum apical size 25, alcohol pellet to clear resin sealer.
Apply OCHWA rubber-dam/isolation requirements. High-yield: rubber dam mandatory at every stage (investigation, prep, filling, definitive restoration including post prep/placement); prefer the cuff technique for access/vision, single-tooth isolation only for the last standing tooth in an arch. Lower: clamp selection (#9T/#2T incisors-canines, 12a premolars-uppers, #4 lower molars).

Occlusal Trauma & Abfraction

Define occlusal trauma and recognise its surrogate clinical signs (injury to the periodontium when occlusal force exceeds adaptive capacity; histologic confirmation only). High-yield: fremitus, increasing mobility, widened PDL space, wear facets, tooth migration, discomfort on chewing. Lower: that definitive diagnosis is histologic, not clinical.
Differentiate primary versus secondary occlusal trauma by the state of the supporting periodontium. High-yield: primary = excessive force on normal-height support (high restoration, parafunction), secondary = normal/excessive force on reduced support (periodontitis-compromised tooth). Lower: overlap when both height loss and overload coexist.
Explain the relationship between occlusal force and periodontitis, justifying that occlusion is a cofactor not a cause. High-yield: excessive force does NOT initiate periodontitis or cause irreversible attachment loss; without inflammation it gives only reversible mobility/bone-density loss that recovers on force removal. Lower: weak evidence it may accelerate attachment loss when superimposed on plaque-induced disease (squirrel-monkey, beagle models).
Justify that occlusal therapy is an adjunct, never a substitute for plaque control. High-yield: treat with occlusal adjustment/splint to reduce mobility, improve comfort and masticatory function; conventional perio + plaque control remains primary. Lower: possible enhanced healing when frank occlusal-trauma signs present.
Describe the abfraction lesion well enough to identify it clinically. High-yield: sharp wedge/V-shaped notch at the cervical CEJ margin, often deeper than wide, crisp internal line angles, hard smooth dentine, buccal of premolars/canines. Lower: distinguish a true notch from generalised cervical dishing.
Explain abfraction’s proposed etiology while acknowledging the contested evidence base. High-yield: theory = eccentric/parafunctional loading concentrates cervical tensile/compressive stress at the CEJ → flexure and micro-fracture; NCCLs are almost always multifactorial (stress + erosion + abrasion). Lower: support is mainly FEA with arbitrary force assumptions; split-mouth removal of interferences did not slow progression; no credible link to recession.
Differentiate the four NCCLs and run a diagnostic work-up before treating. High-yield: abfraction (sharp wedge), abrasion (broad rounded dish), erosion (shallow glossy saucer), attrition (flat facets); screen diet/GORD, brushing force, parafunction; score erosive wear with BEWE. Lower: many NCCLs are non-progressive and simply monitored if asymptomatic.
Apply the restore-versus-monitor decision and select cervical materials. High-yield: restore for hypersensitivity, active progression, structural/caries risk, RPD abutment, or aesthetics, else desensitise + monitor; choose RMGI/GIC (chemical bond, fluoride, flexure/moisture tolerance) or low-modulus/flowable composite where aesthetics dominate. Lower: aggressive restoration alone fails — unmanaged cervical flexure debonds margins and recurs.
Apply Class V restorative technique, recognising isolation as the key challenge. High-yield: rubber dam + cervical clamp or retraction cord; freehand vs Howe transparent matrix vs GIC injection; conserve structure, bond to dentine/enamel margins. Lower: gingival-margin moisture control is the main failure point — see Class V Clinical Summary for full technique.
Justify the OHI and occlusal management that address the cause, not just the lesion. High-yield: atraumatic brushing — soft brush, low-abrasive paste, modified Bass, electric brush with pressure sensor; eliminate premature contacts/excursive interferences, night guard for bruxism. Lower: acid/diet counselling and fluoride/desensitising agents as co-factor control.

Dental Ceramics and Luting Cements Overview

Apply the master etchability rule that dictates every all-ceramic bonding protocol (glass phase present vs absent). High-yield: glass-matrix ceramics (feldspathic, leucite, lithium disilicate, ZLS) are HF-etchable → 9% HF + silane (MPS); polycrystalline zirconia/alumina, glass-infiltrated, and resin-matrix hybrids are NOT HF-etchable → airborne-particle abrasion (~50 µm Al₂O₃, ~1–2 bar) + 10-MDP primer. Lower: HF dissolves leucite to a honeycomb/zirconia stays dissolved in ZLS glass so still etchable, HF actively destroys PICN/RNC polymer network.
Select the onlay material from the load/clearance/aesthetics matrix and name it (the flagged GDP scenario: zirconia onlay → resin cement). High-yield: zirconia (Y-TZP, >900 MPa) for high-load/limited clearance, lithium disilicate (e.max, ~360 MPa) for aesthetic load-bearing posterior, gold for ultimate longevity at thinnest section/minimal prep, composite/CAD-CAM (CERASMART, Lava Ultimate, Enamic ~150–240 MPa) for budget/repairability. Lower: ZLS (Celtra Duo, Suprinity ~370–420 MPa) as a tougher glassy alternative, glass-infiltrated In-Ceram superseded.
Justify the zirconia luting protocol since it is the single most exam-flagged onlay pairing. High-yield: adhesive (or self-adhesive MDP) resin cement after sandblasting + 10-MDP primer (Panavia V5/ED Primer II), Ivoclean to remove saliva phosphate after try-in, NO HF; use self-/dual-cure as light cannot penetrate opaque zirconia; RMGIC/GIC acceptable only on retentive preps. Lower: zinc phosphate historically used on long-axial-wall preps.
Justify the glassy-ceramic (lithium-disilicate/leucite/feldspathic/ZLS) luting protocol. High-yield: adhesive resin cement after 9% HF etch (20 s e.max) + silane (MPS); light-cure if thin/translucent, dual/self-cure if thick. Lower: GIC/RMGIC contraindicated under fragile glass all-ceramics (water-sorption expansion fractures them).
Compare the cement families and rank by adhesion/strength to choose between adhesive and conventional luting. High-yield: resin cements (adhesive needs separate etch/primer/adhesive vs self-adhesive containing MDP) = highest bond + aesthetics; RMGIC fluoride-releasing/stronger than GIC but expands; conventional non-adhesive (zinc phosphate, GIC) fine for full-metal/PFM and well-retentive preps (~6° taper, long walls). Lower: zinc polycarboxylate chelates calcium but low strength, zinc phosphate soluble/acidic on set.
Select the curing mode from restoration thickness and translucency. High-yield: light-cure for translucent restorations <1.5 mm; dual-cure 1.5–2.5 mm; self-/chemical- or dual-cure for zirconia and thick/opaque where light cannot reach. Lower: self-cure has poorer colour stability so avoid under thin/translucent ceramics.
Explain the resin-matrix/hybrid exception and the metal/PFM baseline (when adhesion is and isn’t needed). High-yield: VITA Enamic/Lava Ultimate/CERASMART → air-abrade + resin, NEVER HF; full-metal/PFM → conventional cement acceptable, intaglio sandblast + metal primer only if resin-bonded. Lower: glass-infiltrated In-Ceram behaves as non-etchable (sandblast + primer) despite a glass phase.
Apply the execution and review checklist that protects any cemented onlay margin. High-yield: isolation/rubber dam, prime tooth-before-restoration, low film thickness (ADA max 25 µm), tack-cure ~1–3 s, glycerin gel over margins against the oxygen-inhibition layer, post-cement bitewing. Lower: cement shade/abutment colour visually significant only at ~1 mm ceramic (veneers) — negligible ≥1.5–2 mm; resin-bonded restorations must be sectioned to remove.
For the full luting-cement chemistry and Panavia/Variolink clinical workflows, see MIR LOs. High-yield: cross-reference the MIR “Biomaterials and Luting Cements” objectives for cement classification, bonding mechanisms, and the clinical protocols underlying these decisions. Lower: comparative microleakage tables, compomer and zinc-polycarboxylate niche chemistry.

Pharmacology Resources

GDP high-yield medications

The GDP exam tips flag four common medications to know cold — what they are and when they’re used. Drawn from Resources for Pharmacology:

Aspirin — antiplatelet / NSAID (irreversible COX inhibition, ↓ thromboxane A₂); used for ACS, ischaemic stroke/TIA and as a mild–moderate analgesic. Dental: ↑ bleeding risk — generally continue, control with local measures, avoid stacking NSAIDs (see L21 Haematology Summary, L17 Analgesics and Local Anaesthetics Summary).

Warfarin — vitamin-K antagonist (↓ factors II, VII, IX, X); for VTE, atrial fibrillation, stroke/TIA. Dental: don’t stop without GP advice — check INR within 24 h, proceed if INR < 3.5; avoid NSAIDs, watch metronidazole/azole/macrolide interactions (see L21 Haematology Summary).

Atorvastatin — statin (HMG-CoA reductase inhibitor) for dyslipidaemia / cardiovascular-risk reduction. Dental: CYP3A4 metabolism — macrolides and azole antifungals ↑ statin levels and myopathy risk (see L6 Cardiovascular System Summary).

Dapagliflozin — SGLT2 inhibitor (↑ urinary glucose excretion) for type-2 diabetes. Dental: genital/urinary infections and candidal susceptibility; euglycaemic DKA risk if fasting/unwell (see L13 Endocrine - Diabetes Thyroid Adrenal Summary).

Medical & Drug History

Explain why a structured medical history is the foundation of safe care and a Code-of-Conduct professional duty (personal–medical–dental components, systems review, allergies, medications, social/lifestyle history). High-yield: medical history prevents avoidable medical complications; screen systematically by body-system category — cardiovascular, bleeding/clotting, respiratory, neurological, GI, endocrine, renal/hepatic, bone-modifying, psychological, cancer/radiation, infectious, pregnancy, allergies, medications — so no condition is missed. Lower: medico-legal duty, factual/legible/non-judgmental records, confidentiality, continuity of care, occupational/social influences.
Apply combined open and closed questioning to elicit complete, reliable information and reconcile what the patient says against what they take. High-yield: a drug list is a back-door diagnosis — reverse-engineer each medicine to its condition (metformin/insulin → T2DM, inhaler/salbutamol → asthma, bisphosphonate/denosumab → osteoporosis + MRONJ risk, aspirin → cardiovascular/AF), cross-check verbal answers against the actual medication list, and record every agent including injections, OTC, herbals, vitamins, and supplements. Lower: closed = brief Yes/No for medical screen, open = What/When/Who/Where/Which/How for detail, a signature ≠ comprehension so verify unclear answers.
Apply medication reconciliation to surface undisclosed conditions, polypharmacy, and interaction risk. High-yield: confirm dose, indication, adherence and recency for each drug; flag complementary agents that interact — SSRIs, fish oil, St John’s Wort — and treat any gap between stated history and medication list as a prompt for further questioning. Lower: rationale for capturing recreational substances, smoking/vaping, and alcohol with product, quantity, and duration.
Interpret findings using ASA physical-status grading to decide whether to proceed, modify, or defer treatment. High-yield: ASA I = healthy, II = mild well-controlled systemic disease, III = severe/limiting disease, IV = constant life-threatening disease, V/E = moribund/emergency; rising class lowers the threshold to modify or defer (shorten appointments, optimise timing, ensure emergency preparedness, obtain medical clearance). Lower: ASA is a risk-communication shorthand, not a precise predictor; the lecture frames this as case-by-case judgement rather than fixed cut-offs.
Distinguish true allergy from intolerance/adverse effect and act on the difference. High-yield: confirm the nature and severity of a reported allergy (e.g. childhood penicillin) before discarding a useful drug class — true immune allergy (rash, angioedema, anaphylaxis) contraindicates and demands a safe alternative, whereas intolerance/side-effect (GI upset, nausea) does not. Lower: documenting the reaction so future prescribers can act, and the medico-legal weight of an accurate allergy record.
Recognise how specific systemic conditions modify or delay invasive treatment, using risk to drive sequencing. High-yield: bleeding risk (aspirin/antiplatelets, von Willebrand → bleeding precautions before scaling/extractions), emergency preparedness (asthma, well-controlled epilepsy → seizure/wheeze readiness), impaired healing + hypoglycaemia (diabetes → appointment timing), and MRONJ from denosumab/bisphosphonates → consider delaying or avoiding extractions. Lower: osteoradionecrosis after head/neck radiotherapy, renal/hepatic effects on drug choice (e.g. stage 3 CKD), and pregnancy/infectious-disease precautions.

Anticoagulants, Antiplatelets & Bleeding

Describe normal haemostasis and the coagulation cascade as the framework for antithrombotic drug action (orienting basics before drug mechanisms). High-yield: primary haemostasis = unstable platelet plug, secondary haemostasis = cascade stabilising it; intrinsic + extrinsic pathways converge on the common pathway (X → Xa → fibrin); plasmin lyses the clot. Lower: individual intrinsic factors XII/XI/IX/VIII, platelet-phospholipid mobilisation, classifying anticoagulants into heparins/DTIs/Xa-inhibitors/warfarin.
Distinguish anticoagulant from antiplatelet mechanisms (drug-class map for bleeding-risk SAQs). High-yield: heparins bind ATIII → inactivate IIa & Xa; factor Xa inhibitors (apixaban, rivaroxaban) block Xa; dabigatran inhibits thrombin; warfarin = vitamin-K antagonist of II, VII, IX, X; antiplatelets act on platelets not the cascade. Lower: injectable LMWHs (enoxaparin/Clexane, dalteparin, danaparoid), fondaparinux.
Explain aspirin as an antiplatelet and its dental management (most-flagged GDP drug). High-yield: irreversibly inhibits COX → ↓ thromboxane A₂ → ↓ platelet aggregation (lasts platelet lifespan ~7–10 days); signals CVD/ACS/ischaemic stroke/TIA; do NOT stop low-dose aspirin for routine dental surgery — manage with local measures (pressure, sutures, TXA 4.8% mouthwash); avoid adding NSAIDs. Lower: dipyridamole (PDE inhibitor → ↑ cAMP), GP IIb/IIIa inhibitors (eptifibatide, tirofiban — SAS only).
Explain P2Y₁₂ antagonists and dual antiplatelet therapy risk (clopidogrel/ticagrelor/prasugrel). High-yield: block the platelet P2Y₁₂ receptor; DAPT (aspirin + a P2Y₁₂ agent) markedly raises bleeding risk yet is still managed with local measures rather than stopping; treat in the morning. Lower: prasugrel/ticagrelor metabolised via CYP3A4 (↑ bleeding with macrolides/azoles); opioids delay platelet inhibition.
Explain warfarin’s mechanism, monitoring, and the dental decision rule (single highest-yield GDP item). High-yield: competitively inhibits VKORC1 → ↓ factors II, VII, IX, X; signals AF/mechanical valve/VTE/ischaemic stroke; check INR within 24 h pre-op → proceed if INR < 3.5, defer & refer if > 3.5; do not interrupt unless the GP advises; reverse with vitamin K (Konakion). Lower: CYP2C9 (S-warfarin) and CYP1A2/3A4 (R-warfarin) metabolism; some guidance extends to INR ≤ 4.0.
Distinguish DOACs from warfarin in dental management (no INR, dose-timing rule). High-yield: apixaban/rivaroxaban → factor Xa, dabigatran → thrombin; need no INR monitoring; for low-bleed procedures do not alter dosing, for higher-bleed procedures miss the morning dose (apixaban, dabigatran) or delay it (rivaroxaban, edoxaban) and treat in the morning. Lower: reversal idarucizumab (dabigatran)/andexanet alfa (Xa inhibitors); DOACs are P-gp substrates raised by macrolides/azoles; no evidence for TXA mouthwash in DOACs.
Recognise bleeding risk in relation to the planned procedure and stratify accordingly (procedure × patient factors). High-yield: low-bleed = exams, restorations, RCT, ortho; lower-risk surgical = 1–3 non-adjacent extractions, subgingival debridement; higher-risk = ≥4 or adjacent extractions / any mucoperiosteal flap (surgical extraction, implant, periapical/perio surgery) → consider referral. Lower: additive patient factors — hypertension, renal/liver impairment, prior stroke, labile INR, frailty, hazardous alcohol, low-dose aspirin itself.
Apply local haemostatic measures for patients on antithrombotics (chairside protocol). High-yield: pressure is the single most important haemostatic measure; minimise trauma, pack with oxidised cellulose/collagen, suture; tranexamic acid 4.8% mouthwash (10 mL, rinse 2 min then spit, 4×/day for 2 days) stabilises clots by blocking plasminogen/plasmin binding to fibrin. Lower: compound by crushing a 500 mg TXA tablet in 10 mL water; no TXA-mouthwash evidence in DOACs.
Explain drug interactions and analgesic/antibiotic choice in antithrombotic patients (prescribing safety). High-yield: use paracetamol, avoid NSAIDs/aspirin; warfarin INR raised by metronidazole, azoles (fluconazole), macrolides, tetracyclines, NSAIDs, tramadol. Lower: DOAC levels raised by macrolides/azoles (P-gp); P2Y₁₂ agents via CYP3A4; opioids delay platelet inhibition.
Identify drugs for anaemia and the oral signs of haematopoietic disorders (brief, lower-frequency). High-yield: iron (Hb/myoglobin), vitamin B₁₂ and folate (DNA synthesis/erythropoiesis); pale mucosa, glossitis, angular cheilitis. Lower: erythropoietin agonists (epoetin alfa/Eprex, darbepoetin/Aranesp); mucositis care, antifungals for candidiasis.

Cardiovascular Drugs

Recognise the at-risk cardiac patient from their cardiovascular drug list and apply chairside positioning/monitoring precautions (read the whole medication list as one CV-risk picture). High-yield: atorvastatin/statins flag dyslipidaemia and atherosclerotic CV risk — a sentinel for ischaemic heart disease, prior MI/stroke; orthostatic/postural hypotension is common, so sit the patient up slowly, use short stress-reduced appointments, aspirate before LA, monitor BP/HR, and defer/refer the unstable patient. Lower: head-above-heart positioning in heart failure to limit pulmonary congestion, confirming any infective-endocarditis prophylaxis need with the cardiologist.
Classify the major antihypertensive classes by suffix and site of action. High-yield: ACE inhibitors (-pril), sartans/ARBs (-sartan), calcium channel blockers (-dipine dihydropyridines act on vessels; verapamil/diltiazem act on heart/rhythm), beta blockers (-olol; cardio-selective β1 metoprolol/atenolol/bisoprolol vs non-selective propranolol vs mixed α/β carvedilol/labetalol). Lower: α1 blockers (prazosin), centrally-acting/other vasodilators (clonidine, methyldopa, hydralazine, minoxidil).
Explain the renin–angiotensin system and where antihypertensives act. High-yield: renin makes angiotensin I from angiotensinogen, ACE converts I→II (lungs), angiotensin II acts on AT1 receptors → vasoconstriction, aldosterone/salt retention; ACE inhibitors block I→II and reduce bradykinin breakdown (cough/angioedema), sartans competitively block angiotensin II at AT1. Lower: AT1-driven cardiac hypertrophy/fibrosis, vasopressin release, thirst/salt appetite.
Interpret hypertension grading and the thresholds at which dental treatment is modified or deferred. High-yield: Grade 1 = 140–159/90–99, Grade 2 = 160–179/100–109, Grade 3 = >180/>110 mmHg (defer elective care and refer urgently); treat to cut premature CV morbidity/mortality and microvascular damage to brain, kidney, retina. Lower: primary vs secondary HTN, BP = CO (SV × HR) × systemic vascular resistance modified by volume/viscosity/elasticity.
Recognise the oral/dental side effects of cardiovascular drugs. High-yield: CCBs (esp. nifedipine) cause gingival overgrowth/hyperplasia (reinforce OHI, recurs after surgical removal, refer for medication review); ACE inhibitors → angioedema (lips/face/tongue), dysgeusia, dry/burning mouth; beta blockers → xerostomia, dysgeusia, oral lichenoid reactions; amiodarone → oral/skin pigmentation and taste disturbance. Lower: ACE-induced lichenoid reactions, statin-related pulp-chamber calcification, neutropenia/blood-dyscrasia flags.
Explain the key cardiovascular drug interactions with dental prescriptions. High-yield: NSAIDs cut antihypertensive efficacy and raise renal/hyperkalaemia risk (prefer paracetamol, limit NSAIDs ≤5 days); the “Triple Whammy” (ACE inhibitor + diuretic + NSAID) → acute kidney injury; macrolides (erythromycin/clarithromycin) and azole antifungals are CYP3A4 inhibitors that raise statin levels → myopathy, and interact with diltiazem/verapamil (QT prolongation) and digoxin. Lower: quinapril spaced 2 h from tetracyclines, statin–grapefruit/azole interactions.
Apply adrenaline-with-vasoconstrictor cautions in cardiovascular patients. High-yield: non-selective beta blockers + adrenaline-containing LA → unopposed α-vasoconstriction, hypertensive surge with reflex bradycardia — use minimal vasoconstrictor, always aspirate, dose-dependent risk; avoid adrenaline-soaked retraction cord in anginal/ischaemic patients. Lower: adrenaline is acceptable in stable, treated hypertensives at conservative dose; cardio-selective β1 blockers do not carry the same pressor interaction.
Outline chairside management of angina/acute coronary syndrome. High-yield: glyceryl trinitrate — 400 µg spray OR 300–600 µg tablet sublingual, repeat every 5 min up to 3 doses; if pain persists >10 min after 2 doses treat as ACS — call 000, aspirin 300 mg chewed, oxygen if SaO₂ <90% (titrate 90–96%); ensure patients bring their own GTN as not all clinics stock it. Lower: long-acting nitrates (isosorbide di-/mononitrate), other anti-anginals (ivabradine, nicorandil, perhexiline).
Describe heart-failure and antiarrhythmic drug therapy and their dental relevance. High-yield: systolic HF stepwise — ACE inhibitor (→ sartan if cough/angioedema) → beta blocker when stable → aldosterone antagonist (spironolactone) → digoxin/ivabradine → loop diuretic (frusemide); Vaughan Williams antiarrhythmics I–IV (Na blockers, beta blockers, K blockers amiodarone/sotalol, CCBs verapamil/diltiazem). Lower: digoxin has a narrow therapeutic window (GI upset, visual disturbance, arrhythmia — defer if toxic); diastolic HF has no survival-improving drug; well-controlled arrhythmias don’t contraindicate routine care.

Diabetes, Thyroid & Adrenal Drugs

Classify diabetes and infer it from any glucose-lowering drug on the history (metformin, sulfonylurea, insulin, SGLT2/DPP-4/GLP-1 agents flag a diabetic patient). High-yield: T1DM = autoimmune β-cell destruction, onset <25–30 yrs, lifelong insulin, high DKA risk; T2DM = insulin resistance + declining secretion, onset >40–45 yrs, overweight, oral agents ± insulin, HHS rather than DKA. Lower: gestational and secondary types — pancreatic disease, endocrinopathies, glucocorticoid-induced, genetic/post-transplant DM.
Explain dapagliflozin and the SGLT2 inhibitor class as the GDP exam-flagged must-know agent. High-yield: SGLT2 inhibitors block renal glucose reabsorption → glycosuria; dapagliflozin (Forxiga; Xigduo with metformin) and empagliflozin (Jardiance) signal T2DM; characteristic ADRs are genital/candidal infections, polyuria, dysuria, UTI; low intrinsic hypoglycaemia risk that rises with sulfonylurea/insulin. Lower: dyslipidaemia, combination products (Glyxambi, Jardiamet).
Recognise euglycaemic DKA as the dangerous SGLT2-specific trap and adjust appointment planning. High-yield: SGLT2 inhibitors cause euglycaemic DKA (ketoacidosis with near-normal glucose, masked diagnosis) precipitated by fasting/illness/surgery — avoid unnecessary fasting, keep the patient eating, hold the SGLT2 agent ~3 days before any procedure requiring fasting/GA on GP advice. Lower: FDA pre-operative discontinuation guidance, high index of suspicion for unwell diabetics.
Classify insulin preparations and identify hypoglycaemia as the key adverse effect. High-yield: hypoglycaemia is the most frequent and serious ADR; insulin treats diabetes mellitus NOT diabetes insipidus; rapid-acting (NovoRapid, Humalog, Fiasp) onset ~5 min, short-acting (Actrapid) onset 30 min, long-acting (glargine/Toujeo) ~24 h peakless. Lower: premix human (Mixtard) and analogue premixes (NovoMix, Ryzodeg), pump/CGM delivery; insulin + sulfonylurea carry the highest hypoglycaemia risk.
Explain the mechanisms of the oral hypoglycaemic classes. High-yield: metformin = first line, reduces hepatic glucose output + increases peripheral uptake, no weight gain, taste disturbance, low solo hypoglycaemia risk; sulfonylureas (gliclazide, glimepiride) increase pancreatic insulin secretion → hypoglycaemia + weight gain. Lower: DPP-4 gliptins, GLP-1 incretin mimetics, acarbose (α-glucosidase), pioglitazone (PPAR-γ), tirzepatide (GIP/GLP-1).
Apply chairside diabetes management and the hypoglycaemia protocol. High-yield: schedule short morning appointments after the patient has eaten and taken medication; conscious hypoglycaemia → stop, give fast-acting glucose (adult 15 g, child ≤25 kg 5 g, >25 kg 10 g), repeat after 15 min, then longer-acting carbohydrate; drowsy/unconscious → call 000 + BLS. Lower: 15 g examples (6–7 jelly beans, 125 mL juice, 150 mL non-diet soft drink); don’t let patient drive, advise medical review.
Relate glycaemic control to healing, infection and periodontal risk. High-yield: diabetes causes impaired healing and raised infection/perio/candidiasis risk; HbA1c is the key control/healing predictor (<7% good, >8% poor, >9% ≈2.9× severe periodontitis risk); favour non-surgical perio, consider antibiotic cover for invasive work in poorly-controlled patients. Lower: bidirectional link — non-surgical perio therapy lowers HbA1c at 3–6 months.
Describe thyroid and adrenal drugs and their dental management briefly. High-yield: hypothyroidism → levothyroxine (T4) (raised TSH = hypothyroid; excess dose mimics hyperthyroidism — tachycardia/anxiety); hyperthyroidism → carbimazole / PTU (PTU also blocks T4→T3) ± beta-blockers; adrenal insufficiency → hydrocortisone ± fludrocortisone with stress-dose increase to prevent Addisonian crisis (prednisolone 10 mg od >3 wks → adrenal suppression). Lower: morning appointments, defer/refer invasive >1 h or fasting/GA cases; hypothyroid oral signs (macroglossia, delayed eruption), hyperthyroid alveolar bone loss.

Anti-resorptives & MRONJ

Classify the anti-resorptive drugs acting on bone and their shared mechanism (osteoporosis/bone-metastasis signalling). High-yield: bisphosphonates 1st-line — alendronate (Fosamax, oral), zoledronic acid (Aclasta/Zometa, IV higher-potency) inhibit osteoclastic resorption; denosumab (Prolia/Xgeva) anti-RANKL monoclonal blocking osteoclast formation. Lower: romosozumab (Evenity) anti-sclerostin (↑formation, ↓resorption); raloxifene, teriparatide, calcium/vitamin D adjuncts.
Explain MRONJ pathophysiology and definition as the major dental concern of anti-resorptives. High-yield: exposed maxillofacial bone persisting >8 weeks on a bisphosphonate, denosumab, or anti-angiogenic, with no prior jaw radiation/metastasis; precipitated by extraction, implant placement, periodontal scaling. Lower: multifactorial — antiangiogenics (bevacizumab, sunitinib, cabozantinib, lenvatinib), genetic polymorphism; rare non-MRONJ effects (bisphosphonate glossitis, denosumab lichen planus).
Recognise the risk-factor modifiers that raise MRONJ likelihood (stratify patient risk). High-yield: IV/injectable > oral, cancer indication > osteoporosis, longer duration all higher risk; concurrent glucocorticoids and diabetes, plus immune compromise, anaemia, tobacco, periodontal disease, denture trauma, local suppuration. Lower: dose, pre-existing oral disease as multiplicative cofactors; romosozumab MRONJ comparatively rare.
Apply dental management and prevention strategies for at-risk patients (clearance, atraumatic technique, consent). High-yield: complete invasive treatment before or within 6 months of starting therapy, prioritise prevention, atraumatic technique, suture flaps, pre/post-op chlorhexidine, refer if bone visible at 8 weeks; do NOT routinely stop the drug without specialist/prescriber advice. Lower: antibiotic prophylaxis NOT recommended for prevention, no evidence drug holidays reduce risk, avoid/monitor NSAIDs with bisphosphonates (gastric ulceration); benefits generally outweigh risks.
Outline the other obesity/osteoporosis agents and their chairside relevance (background pharmacology). High-yield: GLP-1/GIP weight agents — semaglutide (Ozempic), liraglutide (Saxenda), tirzepatide (Mounjaro) cause GI nausea affecting chair tolerance; orlistat (Xenical) GI lipase inhibitor → faecal urgency in long appointments. Lower: phentermine (Duromine) and naltrexone+bupropion (Contrave) cause xerostomia — avoid tramadol (serotonin toxicity, CYP2D6), opioids ineffective on Contrave.

Analgesics & Local Anaesthetics

Classify analgesics and match each class to pain type when planning dental analgesia (nociceptive vs neuropathic). High-yield: non-opioid (paracetamol, NSAIDs) and weak/strong opioids treat nociceptive pain; neuropathic pain → TCAs and antiepileptics first-line, opioids only partially. Lower: pain is often mixed, LAs not used for nociceptive pain.
Explain the mechanisms of the non-opioid analgesics and select COX selectivity appropriately (paracetamol vs NSAIDs). High-yield: paracetamol = central prostaglandin-synthesis inhibition, negligible anti-inflammatory effect; NSAIDs inhibit COX — nonselective (ibuprofen, aspirin, naproxen, diclofenac) hit COX1&2, selective (celecoxib, meloxicam) hit COX2 only. Lower: paracetamol MOA not fully determined.
Apply the acute-dental-pain analgesic ladder and prescribe correct regimens, escalating only as needed. High-yield: mild–moderate = ibuprofen 400 mg q6–8h (≤5 days) + paracetamol 1000 mg q4–6h, or celecoxib 100 mg bd; severe acute adds oxycodone IR 5 mg q4–6h prn (≤3 days); opioids are adjuncts, never replace definitive treatment. Lower: combination beats either drug alone, reassess at 5 days.
Calculate paracetamol dosing and recognise its safety ceiling and overdose risk. High-yield: 0.5–1 g q4–6h, max 4 g/24h; overdose → hepatotoxicity. Lower: CR 665 mg, 2 tabs q6–8h (max 6 tabs/day); child >1 month 15 mg/kg q4–6h; rectal absorption slow/erratic; hypersensitivity rare.
Explain opioid mechanism, indications, cautions and adverse effects in dental patients (weak opioids, tramadol risks). High-yield: activate opioid receptors; oxycodone IR (S8) 5 mg q4–6h prn, max 3 days for mod–severe acute pain; tramadol (S4) 50–100 mg q4–6h, max 400 mg/24h — many interactions, serotonin syndrome; codeine combos not <12; AEs = dry mouth, drowsiness, constipation, orthostatic hypotension, dose-related respiratory depression. Lower: tapentadol (S8) 50 mg bd, max 500 mg/24h; morphine/fentanyl/methadone for chronic pain/GA, not acute dental; interacts with CNS depressants and SSRIs.
Explain LA mechanism and distinguish amides from esters when choosing and metabolising agents. High-yield: reversible, dose-dependent sodium-channel block preventing impulse initiation; amides (lidocaine, articaine, mepivacaine) metabolised in liver, esters (procaine, benzocaine) in plasma. Lower: cocaine was the first LA; articaine has both amide and ester properties.
Select first-line LA preparations and techniques for routine and contraindicated-adrenaline cases. High-yield: lidocaine 2% + adrenaline first line; prilocaine + felypressin when adrenaline contraindicated (sulfite sensitivity, pregnancy); articaine 4% for infiltration only — never IAN/lingual/mental blocks. Lower: infiltration, nerve block, intra-ligamentary, intra-pulpal, topical; ropivacaine/bupivacaine for ~12–18 h analgesia; mepivacaine shorter-acting.
Calculate the maximum safe LA dose by weight, convert to cartridges, and recognise toxicity. High-yield: lidocaine 2% = 20 mg/mL, 7 mg/kg → 70 kg adult = 490 mg = 24.5 mL = 11 cartridges (2.2 mL each); aspirate before injecting, lowest effective dose. Lower: early toxicity = anxiety/dizziness/tremors → seizures, CV collapse, methemoglobinemia; bupivacaine more cardiotoxic than ropivacaine.
Recognise local complications of LA administration and the role of vasoconstrictors. High-yield: paraesthesia/dysaesthesia, haematoma, trismus (accidental IM injection) — risk rises with repeat injections/high concentrations; adrenaline prolongs anaesthesia, slows absorption, reduces bleeding (avoid in sulfite-sensitive). Lower: temporary facial nerve paralysis, permanent anaesthesia rare; felypressin safe in pregnancy with minimal cardiac effects.

Antibiotics, Antifungals & Antivirals

Explain the mechanism and dental indication of the core antibacterial classes (cell-wall vs protein-synthesis inhibitors used chairside). High-yield: penicillins/amoxicillin and cephalosporins are bactericidal cell-wall (peptidoglycan/PBP) inhibitors, clindamycin and tetracyclines are bacteriostatic protein-synthesis inhibitors, metronidazole disrupts anaerobic microbial DNA; amoxicillin first-line for odontogenic infection, metronidazole adds anaerobic cover. Lower: glycopeptides, macrolides, full bactericidal/bacteriostatic lists.
Apply Therapeutic Guidelines first-line regimens and doses for spreading odontogenic infection. High-yield: metronidazole 400 mg 12-hourly for 5 days PLUS phenoxymethylpenicillin 500 mg 6-hourly OR amoxicillin 500 mg 8-hourly, single-prep alternative amoxicillin+clavulanate 875+125 mg 12-hourly, necrotising gingivitis = metronidazole 400 mg 12-hourly for 3–5 days. Lower: peri-implantitis amoxicillin 500 mg 8-hourly + metronidazole 400 mg 12-hourly for 7 days, severe/systemic features → IV benzylpenicillin + metronidazole and hospital.
Apply source control as the primary principle — antibiotics do NOT replace dental treatment. High-yield: drain pus / extract / RCT first, localized infection usually needs no antibiotics, start antibiotics only if treatment delayed >24 h or systemic signs present, reassess at 48–72 h. Lower: warm saline/chlorhexidine rinses for pericoronal infection, CT for unresolved abscess, drainage obviates anaerobic cover in healthy hosts.
Select agents for penicillin-allergic patients and apply the cephalosporin cross-reactivity caveat. High-yield: penicillin hypersensitivity → clindamycin 300 mg 8-hourly (treatment) or 600 mg (IE prophylaxis); IE prophylaxis baseline = amoxicillin 2 g 60 min pre-procedure, cefalexin 2 g acceptable for non-severe delayed allergy but avoid cephalosporins after anaphylaxis/angioedema/urticaria. Lower: true cross-reactivity <1% and side-chain dependent, clindamycin carries higher C. difficile risk and ~14% failure rate.
Explain antimicrobial stewardship and resistance as they apply to dental prescribing. High-yield: goal = right drug, dose, duration, only when needed, use narrow-spectrum agents; it is the microbe (not the drug) that changes, four resistance mechanisms = limited uptake, target modification, drug inactivation, efflux pumps, driven by overuse/misuse and incomplete courses. Lower: infection control, surveillance, plasmid/mutation spread.
Select antifungals and antivirals for oral infections and recognise their key interactions. High-yield: oral candidiasis → fluconazole or miconazole (note miconazole inhibits CYP2C9 and dangerously potentiates warfarin → raised INR/bleeding), orolabial herpes simplex → aciclovir; metronidazole + alcohol = disulfiram-like reaction and inhibits warfarin metabolism. Lower: nystatin/amphotericin B topical, itraconazole/voriconazole for immunocompromised, famciclovir/valaciclovir, azoles as broad CYP3A4 inhibitors.

Medical Emergencies & BLS

Apply the DRSABCD sequence and recognise the single most common chairside emergency (syncope, ~40–50% of cases). High-yield: Danger–Response–Send (000)–Airway–Breathing–CPR–Defibrillate; CPR 30 compressions : 2 breaths, assess breathing 10 seconds, attach AED and follow prompts; syncope — recline chair flat, raise legs (head below heart), oxygen, monitor HR/BP. Lower: recovery position before leaving patient alone, do not remove AED pads; hyperventilation — slow nasal breathing, re-breathing into a bag NOT recommended.
Manage anaphylaxis with first-line IM adrenaline by weight (highest-stakes emergency drug fact). High-yield: IM adrenaline into the anterolateral thigh, 10 µg/kg up to 500 µg = 0.5 mL of 1:1000; autoinjector adult/child >20 kg 300 µg, child 10–20 kg 150 µg; repeat every 5 min until response; call 000, lie flat, oxygen. Lower: anaphylaxis = laryngeal swelling + hypotension + bronchospasm; antihistamines (cetirizine, loratadine) and corticosteroid (prednisone) treat mild urticaria/angioedema only, never replace adrenaline; common allergens latex, acrylates; biphasic reaction hours later.
Apply correct EpiPen and Anapen device selection and technique. High-yield: EpiPen 300 µg / Anapen 500 µg for adults >50 kg, EpiPen Jr 150 µg for children 7.5–20 kg; press against outer mid-thigh until click, hold 3 seconds. Lower: EpiPen — remove blue safety release; Anapen — remove black needle shield then grey cap, press red button; keep two doses in the kit.
Manage acute cardiac (ACS/angina) and asthma emergencies with their respective drugs. High-yield: GTN 400 µg spray SL (tablet 300–600 µg), repeat every 5 min, max 3 doses; aspirin 300 mg chewed for severe/new chest pain (suspected MI); salbutamol 4 puffs via spacer then wait 4 min (mild/moderate), severe 12 puffs ≥6 yr / 6 puffs <6 yr or nebulised 5 mg; oxygen if SaO₂ <90%, titrate 90–96%. Lower: angina patients bring own GTN, do NOT resume treatment after recovery — refer; repeat salbutamol every 20 min while awaiting help.
Manage endocrine and neurological emergencies, distinguishing the aspirin indication. High-yield: hypoglycaemia (conscious) — fast glucose adult 15 g, child ≥6 yr/>25 kg 10 g, child ≤5 yr/≤25 kg 5 g, repeat after 15 min; stroke F.A.S.T. and do NOT give aspirin (haemorrhagic stroke not excluded). Lower: drowsy/unconscious — no oral glucose, 000 + BLS; seizure — turn on side, do not restrain or place anything in mouth, observe 30 min, status epilepticus → 000; DKA on SGLT2 → 000.
Describe the emergency drug kit, oxygen and dentistry-specific emergencies. High-yield: kit holds adrenaline (×2), glucose, GTN spray, salbutamol + spacer, aspirin; oxygen via mask 6–8 L/min or nasal prongs 2 L/min, bag-valve mask if not breathing, AED for arrest. Lower: airway foreign body — 5 back blows then 5 chest thrusts (avoid abdominal); methaemoglobinaemia from LA → stop, 000, oxygen; periocular LA paralysis — reassure, patch eye; ocular chemical injury — irrigate ≥15 min, penetrating injury — do NOT remove object or irrigate.

Other Common Drug Classes — Quick Reference

Lower-yield consolidation

The remaining DENT4215 pharmacology summaries are condensed below into class-level objectives — recognise the drug, infer the condition, and apply the chairside precaution. Each links to its full summary.

Recognise the respiratory, gastrointestinal, and renal drug classes on a history and their chairside implications. High-yield: relievers (salbutamol/SABA) vs preventers (inhaled corticosteroids — candidiasis, rinse after use) for asthma/COPD (L7 Respiratory System Summary); PPIs/H2-antagonists/antacids signal GORD with a dental-erosion pattern (L9 Gastrointestinal Summary); diuretics (loop/thiazide/K-sparing) → xerostomia and dose adjustment in CKD (L8 Renal Summary). Lower: theophylline narrow index, antacid–antibiotic chelation, renal dosing of NSAIDs/penicillins.
Recognise neurological and psychotropic drugs and their oral/interaction effects. High-yield: phenytoin → gingival overgrowth (anticonvulsants, L15 Neurology Summary); SSRIs/SNRIs → xerostomia and increased bleeding tendency, TCAs/antipsychotics → xerostomia + caution with adrenaline/sedatives (L16 Psychotropics Summary). Lower: anti-Parkinson and anti-Alzheimer agents, lithium monitoring, serotonin syndrome with tramadol/opioids.
Recognise corticosteroids, immunomodulators, and hormonal agents and the healing/infection risk they confer. High-yield: long-term systemic corticosteroids → adrenal suppression (consider stress dosing) and impaired healing/infection risk; DMARDs/biologics → immunosuppression, delayed healing, infection susceptibility (L18 Immunomodulators and Anti-inflammatory Summary); HRT/combined contraceptives (L11 Hormonal Drugs Summary); topical steroids/retinoids for mucocutaneous lesions (L12 Dermatological Summary). Lower: methotrexate–NSAID interaction, biologic timing around surgery, retinoid mucositis.
Apply the foundational pharmacology principles that underpin dental drug handling. High-yield: ADME, first-pass metabolism, and CYP450 interactions explain most dental drug interactions (L1 Pharmacokinetics Summary); agonist vs antagonist, potency vs efficacy (L2 Pharmacodynamics Summary); dose–response and toxic thresholds (LA and paracetamol overdose) (L3 Toxicology Summary). Lower: ion-trapping/pH–pKa effect on LA in inflamed tissue, volume of distribution, therapeutic index.
Apply safe-prescribing, scheduling, and special-population principles. High-yield: Quality Use of Medicines, drug scheduling (S4 prescription-only, S8 controlled), and valid-prescription requirements (L5 Ethics and Legalities Summary); dose adjustment in paediatric, geriatric, and pregnant patients + herb–drug interactions (L19 CAM and Special Populations Summary); standard precautions, transmission routes, and vaccination (L4 Infectious Disease in Dental Practice Summary). Lower: PBS/private prescriptions, St John’s Wort CYP induction, pregnancy drug categories.

tags	learning-objectives, exam-prep
Field	Clinical Practice
Type	Summary
Related MOCs	MOC GDP
Class	Clinical Dental Practice
Lecturer	Matsubara, Robert Nedelcu, Dr Janina, Dr Cheryl Fu
Related Lecture	L1 Articulators, L2 Introduction to Trios Scanning, L3 Occlusal Splints, L4 Occlusion TMJ and Tooth replacements, L5 Past Year Tx Planning, Resources for Treatment Planning, Resources for Pharmacology
Related Readings
Date created	2026-05-25 10:00
title	CDP LOs
modified	—

Quartz 5

Explorer

CDP LOs

Clinical Dental Practice — Learning Objectives

Course Lectures

L1: Articulators

L2: Intraoral Scanning (Trios)

L3: Occlusal Splints

L4: Occlusion, TMJ & Tooth Replacement

Treatment Planning Resources

Planning Fundamentals, Sequencing & Decision-Making

History Taking & Communication

Clinical Examination & Diagnostic Steps

Diagnosis & Problem List

Tooth Prognosis & Restorability

Periodontitis Staging and Grading

Periodontal Health and Gingival Diseases

Periodontal Abscesses and Necrotizing Periodontal Diseases

Endo-Periodontal Lesions

Peri-Implant Diseases and Conditions

Periodontal Soft-Tissue Root Coverage Procedures

OCHWA Periodontal Treatment Protocol

Endodontic Diagnoses (Pulpal & Periapical)

How to Treat Cracked Teeth

OCHWA Endodontic Guidelines

Occlusal Trauma & Abfraction

Dental Ceramics and Luting Cements Overview

Pharmacology Resources

Medical & Drug History

Anticoagulants, Antiplatelets & Bleeding

Cardiovascular Drugs

Diabetes, Thyroid & Adrenal Drugs

Anti-resorptives & MRONJ

Analgesics & Local Anaesthetics

Antibiotics, Antifungals & Antivirals

Medical Emergencies & BLS

Other Common Drug Classes — Quick Reference

Graph View

Table of Contents

Backlinks